[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 190
1. Goto T, Takano M, Hirata J, Kohno T, Ohtsuka S, Fujiwara K, Tsuda H: p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer. Int J Cancer; 2009 Jul 15;125(2):339-44
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer.
  • The aim of this study is to investigate p16INK4a expression by immunocytochemistry for ascites in advanced ovarian cancer and explore the possibility to predict chemotherapeutic response and prognosis.
  • The immunocytochemical study was performed on cytology of ascites obtained from 37 Stage III or Stage IV ovarian cancer patients with measurable disease before platinum/taxane-based first-line chemotherapy following primary cytoreductive surgery or as neoadjuvant chemotherapy.
  • In vitro expression of p16INK4a protein was also examined for both parent chemosensitive and acquired chemoresistant ovarian cancer cell lines.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ascites / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 UICC.
  • (PMID = 19330839.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


2. Annunziata CM, Kleinberg L, Davidson B, Berner A, Gius D, Tchabo N, Steinberg SM, Kohn EC: BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res; 2007 Nov 15;13(22 Pt 1):6585-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer.
  • PURPOSE: We hypothesized that elevated expression in ovarian cancer of the BAG family of prosurvival proteins and associated partners would be associated with clinical features of aggressiveness in ovarian cancer.
  • EXPERIMENTAL DESIGN: Expression patterns of BAG-1, BAG-3, BAG-4, and Bcl-xL were determined by immunohistochemical analysis of tissue samples obtained at diagnosis from 28 women with stage III or stage IV ovarian cancer treated with cisplatin, paclitaxel, and cyclophosphamide after initial cytoreduction.
  • Association of these proteins, BAG-6, heat shock protein 70 (Hsp70), Hsp27, and Bcl-2, with clinical variables was tested in ovarian cancer tissue arrays from Gynecologic Oncology Group tissue bank.
  • Bcl-2 staining was significantly more frequent on the tissue array in lower stage (P = 0.005) and grade (P = 0.0009) tumors, whereas Hsp70 was prominent in higher grade cases (P = 0.002).
  • Furthermore, Bcl-xL was more closely associated with serous compared with endometrioid ovarian cancers (P = 0.004).
  • CONCLUSION: Unexpectedly, cytoplasmic expression of BAG-4 and Bcl-2 marked less aggressive ovarian cancer, whereas nuclear Hsp70 suggested more aggressive behavior.
  • Bcl-xL may play a more prominent function in the pathology of serous histology ovarian cancers compared with the endometrioid subtype.
  • The findings presented here support involvement of these proteins in the propagation of ovarian cancer and provide a basis for the development of molecular therapeutics modulating these survival pathways.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Apoptosis Regulatory Proteins / metabolism. Carcinoma / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / BAG4 protein, human; 0 / HSP70 Heat-Shock Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein
  •  go-up   go-down


3. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ: AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res; 2010 Oct 1;70(19):7570-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
  • The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested in metastatic disease.
  • In this study, we defined AXL as a therapeutic target for metastatic ovarian cancer.
  • AXL is primarily expressed in metastases and advanced-stage human ovarian tumors but not in normal ovarian epithelium.
  • Genetic inhibition of AXL in human metastatic ovarian tumor cells is sufficient to prevent the initiation of metastatic disease in vivo.
  • Mechanistically, inhibition of AXL signaling in animals with metastatic disease results in decreased invasion and matrix metalloproteinase activity.
  • Most importantly, soluble human AXL receptors that imposed a specific blockade of the GAS6/AXL pathway had a profound inhibitory effect on progression of established metastatic ovarian cancer without normal tissue toxicity.
  • These results offer the first genetic validation of GAS6/AXL targeting as an effective strategy for inhibition of metastatic tumor progression in vivo.
  • Furthermore, this study defines the soluble AXL receptor as a therapeutic candidate agent for treatment of metastatic ovarian cancer, for which current therapies are ineffective.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 AACR.
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):447-54 [9521169.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7123-6 [9507025.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):723-8 [10227296.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9324-39 [16227584.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9294-303 [16230391.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:252-7 [16343241.001]
  • [Cites] Neoplasia. 2005 Dec;7(12):1058-64 [16354588.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3912-20 [16585220.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804 [16585512.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):747-54 [16751775.001]
  • [Cites] J Exp Med. 2006 Aug 7;203(8):1891-901 [16831897.001]
  • [Cites] Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1733-45 [17009964.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):925-34 [17081918.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3878-87 [17440102.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):2806-14 [17332061.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):737-49 [17891189.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):159-85 [17997386.001]
  • [Cites] J Clin Invest. 2008 Feb;118(2):583-96 [18188450.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1905-15 [18339872.001]
  • [Cites] Oncogene. 2008 Jul 3;27(29):4044-55 [18345028.001]
  • [Cites] Adv Cancer Res. 2008;100:35-83 [18620092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10185-90 [18632559.001]
  • [Cites] Cancer Lett. 2008 Sep 18;268(2):314-24 [18502572.001]
  • [Cites] Pathol Int. 2008 Dec;58(12):749-56 [19067848.001]
  • [Cites] Cancer Biol Ther. 2009 Apr;8(7):618-26 [19252414.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3442-55 [19633687.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3107-11 [19738436.001]
  • [Cites] Cell. 2009 Dec 24;139(7):1315-26 [20064377.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9 [20080645.001]
  • [Cites] Cancer Res. 2010 Feb 15;70(4):1544-54 [20145120.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):433-43 [20154587.001]
  • [Cites] Oncogene. 2000 May 4;19(19):2324-30 [10822383.001]
  • [Cites] J Comp Neurol. 2000 Sep 18;425(2):295-314 [10954847.001]
  • [Cites] Nat Med. 2001 Feb;7(2):215-21 [11175853.001]
  • [Cites] Histopathology. 2001 Feb;38(2):87-95 [11207821.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4605-10 [11274374.001]
  • [Cites] Science. 2001 Jul 13;293(5528):306-11 [11452127.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41 [11706404.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):44164-70 [12218057.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5016-31 [1656220.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30022-7 [8939948.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2973-7 [9679957.001]
  • (PMID = 20858715.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009302; United States / NCI NIH HHS / CA / P01 CA067166; United States / NCI NIH HHS / CA / R01 CA116685; United States / NCI NIH HHS / CA / T32 CA009151; United States / NCI NIH HHS / CA / CA67166; United States / NIDDK NIH HHS / DK / U01 DK085527; United States / NCI NIH HHS / CA / F32 CA124082; United States / NCI NIH HHS / CA / T32 CA09151; United States / NCI NIH HHS / CA / CA116685
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / growth arrest-specific protein 6; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / axl receptor tyrosine kinase
  • [Other-IDs] NLM/ NIHMS224661; NLM/ PMC3408227
  •  go-up   go-down


Advertisement
4. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B: Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer; 2005 Jun 1;103(11):2313-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
  • BACKGROUND: The nucleotide excision repair (NER) proteins repair DNA adducts due to xenobiotics and cancer chemotherapy.
  • The authors hypothesized that expression of the NER protein xeroderma pigmentosum A (XPA) would be reduced in a clinically significant fashion in metastatic ovarian carcinoma.
  • METHODS: Malignant effusion specimens were studied so that there was a uniform metastatic ovarian carcinoma population for study.
  • RESULTS: XPA was expressed in cancer cells in 136 of the 142 (96%) effusion specimens.
  • XPA expression did not correlate with treatment status, effusion site, International Federation of Gynecology and Obstetrics stage, histologic grade, or the extent of residual disease.
  • CONCLUSIONS: The results of the current study showed that XPA was widely expressed in metastatic ovarian carcinoma effusion specimens and in the cells of the effusion microenvironment.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Barbolina MV, Adley BP, Kelly DL, Fought AJ, Scholtens DM, Shea LD, Stack MS: Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest; 2008 Jun;88(6):602-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma.
  • Advanced and metastatic ovarian cancer is a leading cause of death from gynecologic malignancies.
  • A more detailed understanding of the factors controlling invasion and metastasis may lead to novel anti-metastatic therapies.
  • To model cellular interactions that occur during intraperitoneal metastasis, comparative cDNA microarray analysis and confirmatory real-time reverse transcription PCR (RT-PCR) were employed to uncover changes in gene expression that may occur in late stage ovarian cancer in response to microenvironmental cues, particularly native three-dimensional collagen I.
  • Gene expression in human ovarian carcinoma tissues was evaluated on the RNA and protein level using real-time RT-PCR and immunohistochemistry.
  • ACTN4 RNA and protein expression were associated with advanced and metastatic human ovarian carcinoma.
  • This report demonstrates that a cytoskeletal-associated protein ACTN4 is upregulated by three-dimensional collagen culture conditions, leading to increased invasion and motility of ovarian cancer cells.
  • Expression of ACTN4 in human ovarian tumors was found to be associated with advanced-stage disease and peritoneal metastases.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharm. 2006 Mar-Apr;3(2):113-23 [16579640.001]
  • [Cites] Hum Pathol. 2006 May;37(5):555-61 [16647953.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5165-72 [16707440.001]
  • [Cites] Am J Clin Pathol. 2006 Jul;126(1):101-9 [16753589.001]
  • [Cites] Yonsei Med J. 2006 Jun 30;47(3):333-42 [16807982.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):4113-21 [16951376.001]
  • [Cites] Mol Carcinog. 2006 Oct;45(10):721-31 [16676365.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(4):345-52 [17009623.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15014-9 [17018644.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):591-8 [16797678.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):793-6 [17023036.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4924-31 [17158885.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):564-9 [17306334.001]
  • [Cites] Obstet Gynecol. 2007 May;109(5):1053-61 [17470582.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6289-98 [12214269.001]
  • [Cites] Gene Ther. 2002 Oct;9(20):1379-86 [12365003.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6278-88 [12414658.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 8;329(2):755-64 [15737651.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):212-7 [15819718.001]
  • [Cites] Mol Cancer Res. 2005 Jul;3(7):365-71 [16046547.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6543-50 [16061633.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):267-77 [12527751.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Nov;82(4-5):323-32 [12589939.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):1-11 [12706853.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1683-90 [12782671.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):129-43 [12784992.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):145-52 [12784993.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):569-74 [12841863.001]
  • [Cites] Z Rheumatol. 2003 Aug;62(4):378-89 [12928942.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):992-5 [14559981.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3262-9 [12855577.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3136-46 [12869505.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Int J Mol Med. 2007 Aug;20(2):139-43 [17611630.001]
  • [Cites] Acta Obstet Gynecol Scand. 2007;86(8):1011-9 [17653889.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Cell. 2007 Aug 24;130(4):601-10 [17719539.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):24-33 [17702616.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Oncogene. 2000 Jan 20;19(3):380-6 [10656685.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Feb;127(2):73-9 [11216917.001]
  • [Cites] Prostate. 2001 May 15;47(3):194-204 [11351349.001]
  • [Cites] Arch Biochem Biophys. 2001 Jun 1;390(1):51-6 [11368514.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24833-42 [11331272.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 23):4197-206 [11739652.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):477-84 [11875718.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4159-65 [12907453.001]
  • [Cites] J Soc Gynecol Investig. 2004 Jan;11(1):51-9 [14706684.001]
  • [Cites] Oncology. 2003;65(4):337-46 [14707454.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2630-9 [15048094.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Biol Chem. 2004 Sep;385(9):801-8 [15493875.001]
  • [Cites] Oncogene. 2004 Oct 21;23(49):8065-77 [15361855.001]
  • [Cites] Chin Med Sci J. 2004 Sep;19(3):170-3 [15506641.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Biol Chem. 1987 Jul 25;262(21):10035-8 [3611052.001]
  • [Cites] Cell. 1993 Jan 29;72(2):223-32 [8425219.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1550-9 [8155119.001]
  • [Cites] Int J Cancer. 1996 Sep 4;67(5):695-701 [8782661.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):193-9 [9367707.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1383-93 [9508771.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1879-85 [9816144.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1635-41 [10197640.001]
  • [Cites] Zentralbl Gynakol. 1999;121(3):126-30 [10209854.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):51-62 [15633123.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Minerva Ginecol. 2004 Dec;56(6):547-56 [15729207.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Sep;17(6):399-411 [16149282.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8836-45 [16204054.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6269-76 [16419154.001]
  • [Cites] Biochem J. 2006 Mar 1;394(Pt 2):449-57 [16232121.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Int J Mol Med. 2006 Apr;17(4):583-90 [16525713.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):207-25 [16359925.001]
  • [Cites] Oncologist. 2006 Mar;11(3):252-60 [16549809.001]
  • (PMID = 18362906.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109545-04; United States / NCI NIH HHS / CA / CA086984-07; United States / NCI NIH HHS / CA / R01 CA086984-09; United States / NCI NIH HHS / CA / R01 CA086984; United States / NCI NIH HHS / CA / R01 CA109545-03; United States / NCI NIH HHS / CA / CA086984-08; United States / NCI NIH HHS / CA / R01 CA86984; United States / NCI NIH HHS / CA / R01 CA086984-07; United States / NCI NIH HHS / CA / CA109545-03; United States / NCI NIH HHS / CA / R01 CA109545; United States / NCI NIH HHS / CA / R01 CA086984-08; United States / NCI NIH HHS / CA / CA086984-09; United States / NCI NIH HHS / CA / CA109545-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTN4 protein, human; 0 / Collagen Type I; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 11003-00-2 / Actinin
  • [Other-IDs] NLM/ NIHMS127548; NLM/ PMC2849305
  •  go-up   go-down


6. Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B: Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer; 2008 Jan 1;112(1):84-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma.
  • BACKGROUND: Death receptors mediate both apoptosis and survival in cancer cells.
  • The authors analyzed death receptor expression in metastatic ovarian carcinoma.
  • METHODS: Viable tumor cells in ovarian carcinoma effusions (n = 95) were analyzed for DR4, DR5, Fas, TNFR1, and TNFR2 expression using flow cytometry.
  • DR4 (P = .005) and TNFR2 (P = .041) expression was higher in FIGO stage IV compared with stage III tumors.
  • CONCLUSIONS: The authors have presented the first evidence of death receptor coexpression in ovarian carcinoma effusions.
  • The association of death receptor expression in effusions with advanced stage, poor response to chemotherapy, and shorter survival suggests that these molecules are linked to an aggressive clinical course in metastatic ovarian carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Ovarian Neoplasms / metabolism. Receptors, Death Domain / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 17985388.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Death Domain
  •  go-up   go-down


7. Fan DM, Shi HR, Chen ZM, Liu HN, Zhang RT: [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1355-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma].
  • OBJECTIVE: To detect the expression of the protein of TGF-beta1 and E-cadherin in the primary and metastatic lesions of ovarian carcinoma and explore the mechanism of the metastasis of ovarian carcinoma.
  • METHODS: Immunohistochemistry (IHC) was performed to detect the expression of TGF-beta1 and E-cadherin proteins in primary and metastatic ovarian carcinoma, benign epithelial ovarian tumor and normal ovarian tissue.
  • RESULTS: The expression of TGF-beta1 was significantly higher in ovarian carcinoma (67.2%) than in benign tumors (28.6%) and normal ovarian tissue (18.9%) (Chi2=26.94, P<0.001), but E-cadherin expression showed a reverse pattern.
  • TGF-beta1 expression in the primary ovarian carcinoma carcinoma was associated with the FIGO stage, lymph metastasis and ascites of the tumor (P=0.01, P=0.01, and P=0.04, respectively).
  • E-cadherin expression in the tumor was associated with the differentiation (P=0.02) and lymph metastasis of ovarian carcinoma (P=0.04).
  • The expressions of TGF-beta1 and E-cadherin were all significantly lower in the primary tumors than in the metastatic tumor (Chi2=4.70, P=0.03; Chi2=5.91, P=0.015).
  • A significant correlation was found between the expressions of the TGF-beta1 and E-cadherin in the primary carcinoma (Kappa value of -0.32, P=0.01).
  • CONCLUSION: TGF-beta1 and E-cadherin are closely associated with the metastasis of ovarian carcinoma and might be potential targets for controlling the metastasis of ovarian carcinoma.
  • [MeSH-major] Cadherins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Transforming Growth Factor beta1 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584638.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


8. McCormick CC, Giuntoli RL 2nd, Gardner GJ, Schulick RD, Judson K, Ronnett BM, Vang R, Bristow RE: The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol; 2007 Jun;105(3):791-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytoreductive surgery for colon cancer metastatic to the ovary.
  • OBJECTIVE: We sought to further elucidate the survival impact of cytoreductive surgery among patients with colon cancer metastatic to the ovary.
  • METHODS: All women diagnosed with primary colon cancer metastatic to the ovary at a single institution from 1980 to 2005 were retrospectively identified.
  • RESULTS: A total of 39 patients with 40 cases of colon cancer metastatic to the ovary were identified.
  • Patients with metastatic disease confined to the ovaries (n=11) had a median overall survival (OS) time of 61 months (range 15-120) compared to 17 months (range 0.5-73) for those with more extensive metastases (n=24) (p=0.0428).
  • CONCLUSIONS: The observation that optimal cytoreduction was associated with prolonged PFS and OS in both patients with localized ovarian and widespread metastases of colon cancer suggests a role for surgical management of metastatic colon cancer in women.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408727.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Aletti GD, Dowdy SC, Podratz KC, Cliby WA: Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol; 2007 Apr;105(1):84-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system.
  • OBJECTIVES: Determine impact of tumor distribution and surgery on prognosis in patients with stage IV epithelial ovarian cancer (EOC).
  • METHODS: Retrospective analysis of stage IV EOC patients undergoing primary surgery between 1994 and 1998.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Triage / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Rafii A, Deval B, Geay JF, Chopin N, Paoletti X, Paraiso D, Pujade-Lauraine E: Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):777-83
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study.
  • The objective of the study is to determine whether surgery influences the outcome of stage IV ovarian cancer.
  • The study design is as follows: From May 1995 to December 2000, 129 patients with FIGO stage IV ovarian cancer, recruited in 42 centers, were prospectively included in GINECO first-line randomized studies of platinum-based regimens with paclitaxel administered simultaneously or sequentially.
  • In conclusion, this study shows a significant benefit of debulking surgery in stage IV ovarian cancer patients who responded to neoadjuvant chemotherapy.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Epithelial Cells / pathology. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367318.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Aletti GD, Podratz KC, Cliby WA, Gostout BS: Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol; 2009 Jan;112(1):22-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
  • OBJECTIVES: We aimed to define the site-specific patterns of treatment failure in stage IV ovarian cancer.
  • METHODS: Data from all consecutive Mayo Clinic patients with stage IV epithelial ovarian cancer, from 1994 through 2003, were collected and analyzed.
  • RESULTS: Review of our patient database identified 109 patients with stage IV ovarian cancer: mean age, 62 years (range, 36-83 years); 5-year overall survival, 15%.
  • Most patients classified as having stage IV disease by pleural cytology only, as opposed to all other patients, had intraperitoneal disease at relapse (88% vs 58.7%, P=.001) and last follow-up (88.5% vs 59.6%, P=.001).
  • Patients having stage IV disease by pleural cytology only had survival benefit when disease was optimally debulked in the abdomen and pelvis (median survival, 3.1 years vs 1.3 years; P=.001).
  • CONCLUSIONS: Clinical trials for stage IV ovarian cancer should reflect the site-specific risks for recurrence according to disease location at diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947860.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


12. Ben-Zvi N, Shani A, Ben-Baruch G, Agmon-Levin N, Sthoeger Z, Huszar M, Ben-Arie A, Dgani R: Dermatomyositis following the diagnosis of ovarian cancer. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1124-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatomyositis following the diagnosis of ovarian cancer.
  • We present a case history of a woman who developed dermatomyositis following the diagnosis of stage IV ovarian cancer.
  • Dermatomyositis is a rare paraneoplastic syndrome that usually precedes the diagnosis of ovarian cancer by several months or years.
  • Ours is the fifth reported case of dermatomyositis after an established diagnosis of ovarian cancer in the literature.
  • [MeSH-major] Dermatomyositis / etiology. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / pathology. Paraneoplastic Syndromes / etiology

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343193.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Immunosuppressive Agents
  •  go-up   go-down


13. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2008 Jan 1;26(1):83-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
  • PURPOSE: To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC).
  • PATIENTS AND METHODS: A retrospective review of 360 patients with International Federation of Gynecology and Obstetrics stage IV EOC who underwent primary surgery followed by six cycles of intravenous platinum/paclitaxel was performed.
  • RESULTS: The median PFS and OS for this group of stage IV ovarian cancer patients was 12 and 29 months, respectively.
  • [MeSH-major] Neoplasm, Residual / etiology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Follow-Up Studies. Humans. Medical Records. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pleural Effusion, Malignant / etiology. Postoperative Complications / etiology. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 1;26(10):1771-2; author reply 1772 [18375912.001]
  • (PMID = 18025437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Mijinyawa MS, Sani MU, Yusuf SM, Mohammed AZ, Alhassan SU: Krukenberg's tumour. Niger J Med; 2009 Oct-Dec;18(4):416-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Krukenburg's tumour, a metastatic cancer to the ovary can pose difficulties in early diagnosis.
  • METHODS: We present a 32-year-old lady who presented with mucoid and bloody diarrhoea associated with menstrual irregularity, weight loss and lower abdominal pains 2 years after surgical treatment for gastric cancer.
  • The histology of the colonic lesion showed signet ring carcinoma while the enlarged ovaries turned out to have evidence of metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Signet Ring Cell / secondary. Colonic Neoplasms / secondary. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120149.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


15. Sterman DH, Gillespie CT, Carroll RG, Coughlin CM, Lord EM, Sun J, Haas A, Recio A, Kaiser LR, Coukos G, June CH, Albelda SM, Vonderheide RH: Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol; 2006 Nov;3(11):633-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon beta adenoviral gene therapy in a patient with ovarian cancer.
  • Background A 47-year-old woman with a history of ovarian cancer and a 6-year disease-free remission presented with dyspnea and increased abdominal girth.
  • The patient was found to have ascites and a large left pleural effusion, both of which contained malignant cells consistent with recurrent ovarian cancer.
  • Diagnosis Stage IV ovarian cancer with malignant ascites and pleural effusion.
  • [MeSH-major] Genetic Therapy. Interferon-beta / genetics. Interferon-beta / therapeutic use. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080181.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 66726
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 77238-31-4 / Interferon-beta
  •  go-up   go-down


16. Ohta S, Yamakawa Y, Hasegawa T, Tateno M, Matsui K: [Advanced ovarian cancer with Sister Mary Joseph's nodule--a case report]. Gan To Kagaku Ryoho; 2007 Jan;34(1):117-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced ovarian cancer with Sister Mary Joseph's nodule--a case report].
  • A metastatic umbilical tumor,which we call Sister Mary Joseph's nodule (SMJN), is a sign of poor prognosis despite the primary site of malignant tumor.
  • We describe here a patient with an advanced ovarian cancer and SMJN.
  • As a result of systemic examination, the patient was diagnosed as stage IV ovarian cancer and rapidly underwent an optimal operation.
  • Postoperatively, the chemotherapy for advanced ovarian tumors was begun (paclitaxel 180 mg/m(2) and carboplatin AUC 5, 10 courses every 3 weeks).
  • [MeSH-major] Abdominal Neoplasms / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Umbilicus

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220685.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Chen MY, Ng KK, Ma SY, Wu TI, Chang TC, Lai CH: False-positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography imaging caused by retained gauze in a woman with recurrent ovarian cancer: a case report. Eur J Gynaecol Oncol; 2005;26(4):451-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography imaging caused by retained gauze in a woman with recurrent ovarian cancer: a case report.
  • We report a case of a 47-year-old woman with a false-positive [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) result caused by retained gauze during resection of liver metastasis for a Stage IV ovarian cancer at primary cytoreductive surgery.
  • However, the former proved to be recurrent ovarian cancer with the latter proven false-positive.
  • [MeSH-major] Adenocarcinoma, Papillary / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Surgical Sponges

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122202.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Dawood SS, Albaracin C, Gonzalez-Angulo A, Markman M, Hennessy B: Effect of introduction of paclitaxel on survival among women with stage III and IV ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of introduction of paclitaxel on survival among women with stage III and IV ovarian cancer.
  • : 5536 Background: The objective of this study was to evaluate survival over time in relation to FDA approval of paclitaxel (P) for second- and first-line treatment in a population-based cohort of women with stage III and de novo stage IV ovarian cancer.
  • METHODS: The Surveillance, Epidemiology, and End Results (SEER) program was searched to identify 8,267 and 10,746 women with stage III and stage IV epithelial ovarian cancer diagnosed between 1988-2004.
  • Women were divided according to their year of diagnosis and year of FDA approval of P for second- (1992) and first-line(1998) treatment of ovarian cancer: Group1 (1988-1991; before P approval); Group2 (1992-1997; P approved for second-line); Group3 (1998-2003; P approved for first-line).
  • Overall (OS) and ovarian-cancer-specific survival (OCS) were estimated using Kaplan-Meier product method and compared across groups with log rank statistic.
  • Median OCS was 44 and 18 months among women with stages III and IV disease, respectively.
  • With stage III disease, 2-year OCS was 64%, 68%, and 70% for groups 1, 2, and 3, respectively (p < 0.0001).
  • With stage IV disease, 2-year OCS was 39%, 41%, and 42% for groups 1, 2, and 3, respectively (p = 0.19).
  • In the multivariable model for stage III disease, women in group 1 (HR = 1.4, 95% CI 1.2-1.5, p < 0.0001) and group 2 (HR = 1.2, 95% CI 1.1-1.3, p = 0.0003) had an increased hazard of ovarian-cancer-specific death vs. group 3.
  • For stage IV disease, women in group 1 (HR = 1.2, 95% CI 1.12-1.3, p < 0.0001) had a significantly increased hazard of ovarian cancer-specific death, but no significant difference in group 2 (HR = 1.0, 95% CI 0.9-1.1, p = 0.88) vs. group 3.
  • CONCLUSIONS: The survival of women with stages III and IV ovarian cancer has significantly improved with the introduction of P over the last two decades.
  • However, the incremental improvement in survival with stage IV disease is clinically minimal and indeed not significant in the univariable analysis in the SEER patient cohort analyzed, suggesting a desperate need for new and more active drugs in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962488.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ravizza D, Fiori G, Trovato C, Maisonneuve P, Bocciolone L, Crosta C: Is colonoscopy a suitable investigation in the preoperative staging of ovarian cancer patients? Dig Liver Dis; 2005 Jan;37(1):57-61
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is colonoscopy a suitable investigation in the preoperative staging of ovarian cancer patients?
  • BACKGROUND: During ovarian cancer surgery, colorectal resection may be required.
  • AIMS: The aim of this study was to evaluate the utility of preoperative colonoscopy in ovarian cancer patients and the prevalence of adenomas in this population.
  • PATIENTS: This retrospective study involved 144 consecutive patients with a supposed primary ovarian cancer.
  • RESULTS: Six patients (4.2%) were excluded because of a misdiagnosed colorectal cancer metastatic to the ovary.
  • CONCLUSIONS: Colonoscopy identifies a not insignificant number of ovarian cancer patients requiring colorectal surgery.
  • [MeSH-major] Colonic Neoplasms / secondary. Colonoscopy. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702861.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, Saunders BA, Pavlik EJ, Goodrich S, Kryscio RJ, van Nagell JR Jr: Predicting risk of malignancy in adnexal masses. Obstet Gynecol; 2010 Apr;115(4):687-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariable classification and regression tree analysis were used to identify a group of patients at high risk of ovarian malignancy.
  • RESULTS: One hundred eighteen patients had ovarian cancer, 13 patients had ovarian tumors of borderline malignancy, and 264 had benign ovarian tumors.
  • Multivariable classification and regression tree analysis defined women at high risk of ovarian malignancy as those with an adnexal mass having complex or solid morphology and a serum CA 125 value greater than 35 units/mL.
  • This definition had a positive predictive value of 84.7% and a negative predictive value of 92.4% and correctly identified 77.3% of patients with stage I and stage II ovarian cancer and 98.6% of patients with stage III and stage IV ovarian cancer.
  • CONCLUSION: Patients with solid or complex ovarian tumors and an elevated serum CA 125 level (greater than 35 units/mL) are at high risk of ovarian malignancy.
  • [MeSH-major] Adnexal Diseases / ultrasonography. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obstet Gynecol. 2010 Apr;115(4):680-1 [20308824.001]
  • (PMID = 20308826.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


21. Ayhan A, Guvenal T, Salman MC, Ozyuncu O, Sakinci M, Basaran M: The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol; 2005 Aug;98(2):235-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries.
  • OBJECTIVE: To investigate the role of cytoreductive surgery in patients with nongenital cancers metastatic to the ovaries.
  • PATIENTS AND METHODS: One hundred and fifty-four patients with nongenital cancers metastatic to the ovaries treated in Hacettepe University Hospital, Gynecologic Oncology Unit between 1982 and 2004 years were retrospectively evaluated.
  • RESULTS: During study period, nongenital cancers metastatic to the ovaries constituted 9% of all malignant ovarian neoplasms.
  • Primary cancers were breast (35), stomach (35) and colorectal (33) cancers, lymphoma (17), undetermined origin (16), appendix (7), ileum (4), pancreas (3), gallbladder cancer (2) and mesothelioma (2).
  • CONCLUSION: Presence of ovarian metastasis is associated with a poor prognosis in nongenital cancers.
  • Cytoreductive surgery seems to have a beneficial effect on survival of selected patients, especially for patients with colorectal cancer metastatic to the ovary.
  • [MeSH-major] Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982725.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Micha JP, Goldstein BH, Epstein HD, Rettenmaier MA, Brown JV 3rd: Ovarian cancer metastatic to the breast. Gynecol Oncol; 2006 Aug;102(2):386-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer metastatic to the breast.
  • BACKGROUND: Metastatic ovarian cancer to the breast should be considered in the differential diagnosis for gynecologic cancer patients with a breast tumor.
  • CASES: We present three ovarian cancer patients who developed metastatic ovarian cancer to the breast.
  • All patients were heavily pre-treated prior to the development of metastatic disease.
  • Currently, one patient is alive at 64 months following initial detection of her metastatic disease to the breast.
  • The second and third patients are also alive for 30 and 3 months subsequent to their diagnosis of metastatic disease.
  • CONCLUSION: Although metastatic ovarian cancer to the breast following treatment for ovarian cancer is rare and associated with a poor prognosis, oncology physicians should be prepared to contend with disease metastatic to the breast.
  • [MeSH-major] Breast Neoplasms / secondary. Ovarian Neoplasms / pathology


23. Brunisholz Y, Miller J, Proietto A: Stage IV ovarian cancer: a retrospective study on patient's management and outcome in a single institution. Int J Gynecol Cancer; 2005 Jul-Aug;15(4):606-11
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV ovarian cancer: a retrospective study on patient's management and outcome in a single institution.
  • The management of stage IV epithelial ovarian carcinoma remains controversial.
  • A retrospective database and casenote review was performed on all patients diagnosed with stage IV disease over a ten-year period (1992-2002).
  • Debulking surgery can be performed in patients with stage IV ovarian cancer, with an acceptable level of morbidity.
  • [MeSH-major] Neoplasm Metastasis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014113.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A: Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol; 2010 Jun;17(6):1642-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
  • BACKGROUND: One of the most important prognostic factors in advanced ovarian cancer is the macroscopic absence of residual tumor after primary surgery.
  • The impact of surgical outcome on the survival of patients with International Federation of Gynecology and Obstetrics (FIGO) stage IV disease is less clear and is the subject of this study.
  • In these studies, 573 patients with FIGO stage IV disease were first operated, then randomized and homogenously treated with a combination therapy comprising the intravenous application of platinum and paclitaxel.
  • RESULTS: The median progression-free survival and overall survival of patients with stage IV ovarian cancer were 12.6 and 26.1 months, respectively.
  • CONCLUSIONS: Macroscopically complete resection in FIGO stage IV disease, irrespective of the site of distant tumor spread, is an important prognostic factor and the only prognosticator amenable to improvement by therapy.
  • Our results suggest possible advantages of a reasonable attempt at complete cytoreduction even in FIGO stage IV disease.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20165986.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Bulanova IM, Bulanova TV, Burenchev DV: [Ultrasonography and magnetic resonance imaging in diagnosing recurrent and metastatic ovarian cancer]. Vestn Rentgenol Radiol; 2006 Jan-Feb;(1):53-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrasonography and magnetic resonance imaging in diagnosing recurrent and metastatic ovarian cancer].
  • The paper deals with the capacities of ultrasonography (USG) and magnetic resonance imaging (MRI) in diagnosing recurrent and metastatic ovarian cancer along with routine clinical and laboratory studies (physical examination, measurement of the tumor-associated serum antigen CA-125) in 95 patients with ovarian cancer after primary special treatment.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / ultrasonography. Ovarian Neoplasms / pathology. Ovarian Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195634.001).
  • [ISSN] 0042-4676
  • [Journal-full-title] Vestnik rentgenologii i radiologii
  • [ISO-abbreviation] Vestn Rentgenol Radiol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


26. Bolis G, Scarfone G, Raspagliesi F, Mangili G, Danese S, Scollo P, Lo Russo D, Villa A, Aimone PD, Scambia G: Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer; 2010 Nov;46(16):2905-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.
  • OBJECTIVE: The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities.
  • METHODS: Eligible for the study were patients aged at least 18 years old with histological/cytological diagnosis of FIGO stages III (residual tumour ≥1 cm after primary surgery)--IV epithelial ovarian cancer.
  • Patients were randomized to iv PC on day 1, every 21 days or iv topotecan daily for three days and PC on day 3, every 21 days.
  • CONCLUSION: The results of the present study show that the addition of topotecan to a standard paclitaxel/carboplatin regimen in the treatment of advanced epithelial ovarian cancer did not result in significant advantages in terms of survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ltd.
  • (PMID = 20673626.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Iyibozkurt AC, Akhan SE, Topuz S, Citil I, Berkman S: Laparoscopic evaluation of metastatic ovarian cancer: a case report. Eur J Gynaecol Oncol; 2005;26(1):123-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic evaluation of metastatic ovarian cancer: a case report.
  • OBJECTIVE AND CASE: Both noninvasive and invasive methods have limited value in the diagnosis of metastatic ovarian cancer.
  • We present a case with the initial complaint of abdominal distention in whom primary and metastatic tumor sites were safely diagnosed by using laparoscopy: a gastric tumor with ovarian metastasis.
  • DISCUSSION: Diagnostic laparoscopy by the open technique provides a safe and effective diagnostic option in patients with metastatic ovarian cancer.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Ovarian Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755020.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


28. Brown JV 3rd, Goldstein BH, Duma CM, Rettenmaier MA, Micha JP: Gamma-knife radiosurgery for the treatment of ovarian cancer metastatic to the brain. Gynecol Oncol; 2005 Jun;97(3):858-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-knife radiosurgery for the treatment of ovarian cancer metastatic to the brain.
  • BACKGROUND: Central nervous system (CNS) metastases from an ovarian malignancy are uncommon.
  • CASES: We present three ovarian cancer patients who developed metastatic disease to the brain.
  • CONCLUSION: Local control of ovarian cancer metastatic to the brain can be achieved in some patients with GKRS.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Ovarian Neoplasms / pathology. Radiosurgery


29. Walker J, Lane P: Challenges and choices: an audit of the management of nausea, vomiting and bowel obstruction in metastatic ovarian cancer. Contemp Nurse; 2007 Dec;27(1):39-46
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and choices: an audit of the management of nausea, vomiting and bowel obstruction in metastatic ovarian cancer.
  • Women living with metastatic ovarian cancer experience many distressing symptoms, such as vomiting and bowel obstruction, which challenge the expertise of nurses working in Palliative Care to promote quality of life.
  • [MeSH-major] Intestinal Obstruction / therapy. Medical Audit. Nausea / therapy. Ovarian Neoplasms / physiopathology. Vomiting / therapy


30. Yoshihara C, Hamada K, Koyama Y: Preparation of a novel adenovirus formulation with artificial envelope of multilayer polymer-coatings: therapeutic effect on metastatic ovarian cancer. Oncol Rep; 2010 Mar;23(3):733-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation of a novel adenovirus formulation with artificial envelope of multilayer polymer-coatings: therapeutic effect on metastatic ovarian cancer.
  • Therapeutic effect of the intraperitoneal injection of the oncolytic adenovirus with quintal polymer multilayers on the mice bearing intraperitoneal metastatic ovarian cancer was examined.
  • [MeSH-major] Adenoviridae / genetics. Genetic Therapy. Oncolytic Virotherapy. Ovarian Neoplasms / therapy. Polyethyleneimine / administration & dosage


31. Slovacek L, Slanska I, Slovackova B, Petera J, Filip S, Priester P, Kopecky J, Jebavy L: Screening for depression in survivors of metastatic ovarian cancer in a programme of palliative cancer care. Bratisl Lek Listy; 2009;110(10):655-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for depression in survivors of metastatic ovarian cancer in a programme of palliative cancer care.
  • BACKGROUND: Depression is seen in many cancer patients.
  • The statistical evaluation not presents statistically significant dependence of ZSRDS on smoking abuse, marital status, age, number of associated diseases and type of palliative cancer care.
  • CONCLUSION: The results of the pilot depression study showed that subsist clear association between metastatic ovarian cancer and depression (Fig.
  • [MeSH-major] Depression / diagnosis. Ovarian Neoplasms / psychology. Palliative Care


32. Juretzka MM, Horton FR, Abu-Rustum NR, Sonoda Y, Jarnagin WR, Flores RM, Barakat R, Chi DS: Full-thickness diaphragmatic resection for stage IV ovarian carcinoma using the EndoGIA stapling device followed by diaphragmatic reconstruction using a Gore-tex graft: a case report and review of the literature. Gynecol Oncol; 2006 Mar;100(3):618-20
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-thickness diaphragmatic resection for stage IV ovarian carcinoma using the EndoGIA stapling device followed by diaphragmatic reconstruction using a Gore-tex graft: a case report and review of the literature.
  • BACKGROUND: Previous studies have reported the results of full-thickness diaphragmatic resection for ovarian cancer metastatic to the diaphragm.
  • Gore and Associates, Inc., Newark, DE) graft.
  • [MeSH-major] Diaphragm / surgery. Ovarian Neoplasms / surgery. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226799.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


33. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature.
  • The differential diagnosis includes a variety of benign and malignant vascular proliferations (littoral cell angioma and Kaposi's sarcoma) as well as metastatic tumors.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • [MeSH-major] Hemangiosarcoma / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Splenic Neoplasms / pathology


34. Testelmans D, Van Raemdonck D, Amant F, De Wever W, Verbeken E, Nackaerts K: Late recurrent ovarian carcinoma metastatic to the thoracic wall. Acta Clin Belg; 2010 Sep-Oct;65(5):354-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrent ovarian carcinoma metastatic to the thoracic wall.
  • Ovarian cancer is the second most common gynaecologic malignancy.
  • Ovarian carcinomas typically metastasize to multiple sites via exfoliation, lymphatic spread or direct invasion.
  • We present a rare case of a very late recurrence of ovarian carcinoma into the thoracic wall, heralded by thoracic pain in a patient otherwise disease-free for 23 years.
  • This unusual and late presentation of an ovarian cancer metastasis underscores the need for continued awareness and attention to new symptoms in patients with ovarian cancer who show prolonged disease-free intervals.
  • [MeSH-major] Ovarian Neoplasms / pathology. Thoracic Neoplasms / secondary. Thoracic Wall

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21128565.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


35. Wu XF, Chen Y: [Management and prognosis of metastatic ovarian carcinoma from nongenital tract]. Zhonghua Fu Chan Ke Za Zhi; 2005 Jun;40(6):404-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management and prognosis of metastatic ovarian carcinoma from nongenital tract].
  • OBJECTIVE: To study the management and prognosis of nongenital metastatic ovarian carcinoma.
  • METHODS: Thirty-four patients with nongenital metastatic ovarian carcinoma who were admitted in to Zhongnan Hospital of Wuhan University between 1998 and 2004 were analyzed retrospectively.
  • CONCLUSIONS: Most of nongenital metastatic ovarian carcinomas come from tumors of stomach and intestine.
  • Optimal cytoreductive surgery and chemotherapy play an important role in the management and prognosis of nongenital metastatic ovarian carcinoma.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008893.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


36. Tsubono M, Kaneko I, Kii E, Tanaka T, Murata T, Kamimura K, Deguchi Y, Nonogaki H, Yasumizu R: [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. Gan To Kagaku Ryoho; 2005 Mar;32(3):365-9
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
  • A 46-year-old woman who had received mastectomy for breast cancer 6 years earlier complained of abdominal distension.
  • Computed tomography and ultrasonography revealed massive ascites and ovarian swelling of both sides.
  • She was diagnosed as having primary ovarian cancer and peritoneal dissemination, and underwent a total hysterectomy as well as ovarectomy on both sides.
  • After surgery, she received a sequential chemotherapy, ie, intraabdominal injection of carboplatin (CBDCA 300 mg/m2) and div administration of paclitaxel (PTX 180 mg/m2) as a standard regimen for advanced ovarian cancer.
  • However, detailed histological examinations showed that the ovarian cancer had metastasized from her breast cancer.
  • It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted.
  • Therefore, no standard therapy has been established for breast cancer metastasizing to the ovarium.
  • No evidence of recurrence of breast cancer has been noted 1 year after surgery.
  • This result suggests that weekly administration of PTX and intraabdominal injection of CBDCA might be beneficial in the treatment of recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation.
  • [MeSH-major] Adenocarcinoma, Scirrhous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791819.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitriles; 0 / Triazoles; 039LU44I5M / Floxuridine; 2Z07MYW1AZ / anastrozole; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


37. Kullar P, Stonard C, Jamieson N, Huguet E, Praseedom R, Jah A: Primary hepatic embryonal sarcoma masquerading as metastatic ovarian cancer. World J Surg Oncol; 2009;7:55
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic embryonal sarcoma masquerading as metastatic ovarian cancer.
  • CASE PRESENTATION: We report a case of a 52 year old woman having previously undergone treatment for ovarian serous papillary carcinoma who subsequently presented with a large solitary mass in the liver.
  • Initially this was presumed to be metastasis from the ovarian primary however, on further examination it was shown to be a primary hepatic embryonal sarcoma.
  • CONCLUSION: Primary liver tumors should be considered in differential diagnoses in patients with ovarian cancer who subsequently present with liver tumors.
  • This is particularly important when there is no direct evidence of recurrence of ovarian cancer.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Liver Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Sarcoma / pathology


38. Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B: Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer; 2007 Jan 15;109(2):228-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
  • BACKGROUND: Inhibitor of apoptosis proteins (IAPs) mediate cancer cell survival and chemoresistance.
  • The expression of XIAP, Survivin, and Livin in ovarian carcinoma was analyzed.
  • CONCLUSIONS: XIAP and Survivin, but not Livin, are frequently expressed in ovarian carcinoma.
  • [MeSH-major] Cell Nucleus / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17167759.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC5 protein, human; 0 / BIRC7 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


39. Van Trappen PO, Cullup T, Troke R, Swann D, Shepherd JH, Jacobs IJ, Gayther SA, Mein CA: Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer. Gynecol Oncol; 2007 Jan;104(1):129-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer.
  • OBJECTIVE: To date, most mtDNA mutations in cancer have been identified in the control region (D-loop) containing the major promoters.
  • However, almost all studies used one sample per tumor and there is no clear evidence whether metastatic deposits harbor different mtDNA variants.
  • To establish whether different mtDNA variants can be found in the same cancer but at different sites, we analyzed a series of unilateral and bilateral primary epithelial ovarian cancers as well as paired metastatic tumor deposits.
  • METHODS: We sequenced the D-loop region in 52 different tumor samples of 35 ovarian cancer cases, as well as matched normal tissues.
  • Seventeen of those 35 cases had bilateral ovarian cancer, with a sample from each tumor analyzed.
  • RESULTS: Eighty-six polymorphisms (4 new in ovarian cancer) were detected, and 9 different somatic mtDNA mutations were found in 26% (9 of 35) of ovarian cancer cases; all were homoplasmic in nature.
  • Six of the mutations were novel in ovarian cancer.
  • In 24% (4 of 17) of cases with bilateral ovarian tumors, different mtDNA variants were found between paired tumors, suggesting the presence of different clonal populations of cancer cells.
  • Metastatic tumor deposits showed identical mtDNA variants to those found in at least one of the ovarian tumors in cases with bilateral ovarian cancer.
  • [MeSH-major] DNA, Mitochondrial / genetics. DNA, Neoplasm / genetics. Mutation. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16942794.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


40. Kim MJ: The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J Korean Med Sci; 2005 Aug;20(4):643-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
  • Distinguishing primary ovarian carcinoma from metastatic carcinoma to the ovary is often difficult by histologic examination alone.
  • Recently an immunohistochemical marker CDX-2 was found to be of considerable diagnostic value in establishing the gastrointestinal origin of metastatic tumors.
  • Paraffin-embedded tissue sections from 57 primary ovarian tumors and 40 metastatic tumors to the ovary were immunostained for CDX-2, and results were compared to the ancillary immunohistochemical results for CK7/CK20, CEA, CA125, and her-2/neu.
  • CDX-2 immunoreactivity was observed in most of metastatic carcinomas with colorectal (91%) and appendiceal (100%) origin, however CDX-2 was negative in all primary ovarian carcinomas, except for the mucinous subtype.
  • Almost all primary ovarian carcinomas including the mucinous subtype showed diffuse and strong immunoexpression for CK7.
  • CEA and CA125 were mainly found in metastatic and primary ovarian carcinoma, respectively.
  • Her-2/neu overexpression was only noted in a small proportion of primary and metastatic ovarian carcinomas.
  • These results suggest that CDX-2 is very useful immunohistochemical marker for distinguishing metastatic colorectal carcinoma to the ovary from primary ovarian carcinoma, including the mucinous subtype.
  • [MeSH-major] Homeodomain Proteins / analysis. Ovarian Neoplasms / pathology. Tissue Array Analysis / methods. Trans-Activators / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jun;31(6):672-7 [10872659.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Cancer Lett. 2002 Feb 8;176(1):47-55 [11790453.001]
  • [Cites] J Gastroenterol. 2002;37(2):94-100 [11871772.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):769-74 [12239615.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):141-9 [12548159.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jan-Feb;13(1):28-31 [12631216.001]
  • [Cites] Arch Pathol Lab Med. 2003 Dec;127(12):1586-90 [14632574.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):782-6 [14576939.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):52-7 [14668551.001]
  • [Cites] Adv Anat Pathol. 2004 Mar;11(2):101-5 [15090846.001]
  • [Cites] Virchows Arch. 2004 Jul;445(1):63-7 [15175880.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1392-9 [15205684.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):114-21 [3812871.001]
  • [Cites] Am J Clin Pathol. 1992 Jun;97(6):751-8 [1595595.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):219-23 [7506222.001]
  • [Cites] Hum Pathol. 1994 Jul;25(7):666-70 [8026826.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):852-5 [7543441.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):619-25 [8552090.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):426-9 [8729984.001]
  • [Cites] J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105 [8796816.001]
  • [Cites] Mod Pathol. 1996 Nov;9(11):1040-4 [8933513.001]
  • [Cites] Hum Pathol. 1998 May;29(5):491-7 [9596273.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):283-90 [10474521.001]
  • [Cites] J Clin Pathol. 2000 May;53(5):327-34 [10889812.001]
  • (PMID = 16100458.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2782162
  •  go-up   go-down


41. Duong HV, McLean IW, Beahm DE: Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma. Am J Ophthalmol; 2006 Oct;142(4):693-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma.
  • PURPOSE: To report a case of metastatic malignant amelanotic melanoma to the skin from a patient diagnosed with bilateral diffuse uveal melanocytic proliferation (BDUMP).
  • She had previously been diagnosed with ovarian carcinoma, and findings of funduscopic examinations were consistent with BDUMP.
  • Metastatic examination revealed no evidence of liver involvement.
  • RESULTS: The hematoxylin and eosin, S-100, and HMB-45 stains were consistent with metastatic malignant amelanotic melanoma to the skin.
  • CONCLUSIONS: Although believed to have a low potential for metastasis, patients should be monitored and evaluated regularly to detect any new lesions not associated with their primary inciting carcinoma.
  • [MeSH-major] Melanocytes / pathology. Melanoma, Amelanotic / secondary. Ovarian Neoplasms / pathology. Paraneoplastic Syndromes / pathology. Skin Neoplasms / secondary. Uveal Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011873.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


42. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B: NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol; 2006 Mar;125(3):451-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.
  • We studied the clinical role of leukocyte infiltration and chemokine receptor expression in ovarian carcinoma effusions.
  • CXCR4, CCR5, and CCR7 were expressed abundantly on leukocytes, but all receptors were expressed rarely on cancer cells.
  • The presence of natural killer cells (P = .042) and International Federation of Gynecology and Obstetrics (FIGO) stage IV disease (P = .024) predicted worse overall survival (OS).
  • A higher percentage of CD19+ cells (P = .015) and stage IV disease (P = .008) predicted poor survival for patients with postchemotherapy effusions.
  • Only FIGO stage retained significance as a predictor of OS (P = .035) in multivariate analysis.
  • Chemokine receptors are expressed widely on leukocytes but rarely on carcinoma cells in ovarian carcinoma effusions, arguing against an autocrine chemokine pathway in this malignancy.
  • Immune response parameters in ovarian cancer effusions are weak predictors of outcome.
  • [MeSH-major] Adenocarcinoma / secondary. B-Lymphocytes / pathology. Killer Cells, Natural / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613351.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Chemokine
  •  go-up   go-down


43. McLean MA, Priest AN, Joubert I, Lomas DJ, Kataoka MY, Earl H, Crawford R, Brenton JD, Griffiths JR, Sala E: Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. Magn Reson Med; 2009 Oct;62(4):855-61
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T.
  • (1)H-MRS was performed on 12 women (age range 45-72) with ovarian cancer of FIGO stage 3 or above using a 3T MRI system with an 8-channel cardiac receive coil.
  • Respiratory-triggered PRESS-localized spectra (TE = 144 ms) were obtained separately from an ovarian mass and from metastatic disease.
  • Choline was detected in 10/12 primary tumors and 5/11 metastatic lesions (range 2.0-16.6 mM).
  • Glycine was observed in one benign lesion. (1)H-MRS can be used to quantify choline in primary and metastatic masses in ovarian cancer, but the moderately high rate of failure to detect choline necessitates careful recording of data quality parameters to discriminate true from false negatives.
  • [MeSH-major] Biomarkers, Tumor / analysis. Choline / analysis. Glycine / analysis. Magnetic Resonance Spectroscopy / methods. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLYCINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19645005.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; N91BDP6H0X / Choline; TE7660XO1C / Glycine
  •  go-up   go-down


44. Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, Reich R: Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol; 2007 Feb;104(2):311-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
  • OBJECTIVE: To analyze the expression of Heparanase, an enzyme involved in cancer metastasis and angiogenesis, in ovarian and breast carcinoma cells in effusions.
  • METHODS: Heparanase protein expression was analyzed in malignant effusions from ovarian (=200) and breast (=41) carcinoma patients using immunocytochemistry.
  • RESULTS: Heparanase was expressed at the cell membrane in 106/200 (53%) ovarian and 22/41 (54%) breast carcinomas.
  • Cytoplasmic expression was found in 180/200 (90%) ovarian and 26/41 (63%) breast carcinomas.
  • In univariate survival analysis of ovarian carcinoma patients with post-chemotherapy effusions, membrane expression in >5% of tumor cells correlated with shorter overall survival (OS, p=0.013).
  • FIGO stage (p=0.03 for all patients, p=0.045 for those with post-chemotherapy specimens) and response to first-line chemotherapy (p<0.0001 for all patients, p=0.049 for those with post-chemotherapy specimens) were the clinical parameters related to OS.
  • Heparanase expression did not correlate with survival in breast carcinoma.
  • CONCLUSIONS: Our data show that heparanase is frequently expressed in metastatic gynecologic adenocarcinomas, and that it is secreted into the effusion fluid in body cavities.
  • The correlation between heparanase expression and poor survival in ovarian carcinoma suggests a role for this molecule in ovarian cancer metastasis and supports its role as a marker of aggressive clinical behavior at disease recurrence.
  • [MeSH-major] Glucuronidase / biosynthesis. Ovarian Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030350.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


45. Ritchie D, Mileshkin L, Wall D, Bartholeyns J, Thompson M, Coverdale J, Lau E, Wong J, Eu P, Hicks RJ, Prince HM: In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol Immunother; 2007 Feb;56(2):155-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma.
  • We describe the use of two methods of cell labelling for tracking the destination of autologous-derived macrophage activated killer (MAK) cells linked to the bi-specific antibody MDX-H210 delivered either by intravenous (i.v.) or intraperitoneal (i.p.) injection in ten patients with peritoneal relapse of epithelial ovarian carcinoma.
  • MAK cell administration produced minimal infusional toxicity and demonstrated a reproducible pattern of in vivo distribution and active in vivo tracking to sites of known tumour following 8 of 16 i.v. infusions or 4 of 6 i.p. infusions.
  • This data demonstrates that cellular cancer immunotherapies may be successfully delivered to the sites of active tumour following either i.v. or i.p. injection in a proportion of patients with metastatic cancer.
  • [MeSH-major] Carcinoma / immunology. Carcinoma / secondary. Fluorodeoxyglucose F18 / administration & dosage. Killer Cells, Lymphokine-Activated / immunology. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733671.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Indium Radioisotopes; 0 / MDX-H210 antibody; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Behne MJ, Hauswirth U, Menz A, Brüllke N, Müllerleile U, Moll I: [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy]. Hautarzt; 2008 Nov;59(11):917-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].
  • [Transliterated title] Akrale Nekrosen bei metastasiertem Ovarialkarzinom. Ausdruck eines singulären Moschkowitz-Syndroms unter Gemcitabin-Chemotherapie.
  • In the differential diagnosis, Raynaud's syndrome should be considered as a premonitory paraneoplasia, a risk factor for the occurrence of acral necrosis in patients with a malignant tumour undergoing chemotherapy, particularly patients with ovarian carcinoma receiving gemcitabine treatment.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Fingers / pathology. Hand Dermatoses / chemically induced. Hand Dermatoses / therapy. Ovarian Neoplasms / drug therapy. Purpura, Thrombotic Thrombocytopenic / chemically induced. Purpura, Thrombotic Thrombocytopenic / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2007 Apr;30(2):101-5 [17414457.001]
  • [Cites] Br Med J. 1967 Jul 22;3(5559):208-12 [6028467.001]
  • [Cites] Am J Hematol. 1998 Apr;57(4):293-302 [9544973.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2 Pt 2):S21-3 [12928002.001]
  • [Cites] Thromb Res. 1985 Jun 1;38(5):469-79 [2861671.001]
  • [Cites] Zentralbl Bakteriol B. 1978 Sep;167(3):253-61 [104483.001]
  • [Cites] Arthritis Rheum. 1985 Jan;28(1):87-92 [3871330.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Feb;30(2):332-4 [16565677.001]
  • [Cites] Hautarzt. 2006 Oct;57(10):927-38; quiz 941 [16964476.001]
  • [Cites] Dermatologica. 1990;181(3):202-6 [2135387.001]
  • [Cites] Clin Exp Dermatol. 1996 Sep;21(5):381-2 [9136163.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):808-9 [9469381.001]
  • [Cites] DICP. 1989 Jul-Aug;23(7-8):582-8 [2669373.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):547-53 [16470522.001]
  • [Cites] Cancer. 1999 May 1;85(9):2023-32 [10223245.001]
  • [Cites] Clin Rheumatol. 1993 Jun;12(2):281-2 [8358996.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):553-8 [15612026.001]
  • [Cites] Scand J Clin Lab Invest. 1978 Dec;38(8):761-4 [741205.001]
  • [Cites] Hautarzt. 2006 Sep;57(9):819-28; quiz 829 [16902805.001]
  • [Cites] Hautarzt. 1999 Oct;50(10):748-52 [10550363.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1343-9 [2254771.001]
  • [Cites] Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34 [11702367.001]
  • [Cites] Ann Intern Med. 1984 Dec;101(6):798-9 [6497196.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):267-73 [15975643.001]
  • [Cites] Mayo Clin Proc. 1996 Mar;71(3):253-8 [8594283.001]
  • [Cites] Med Klin (Munich). 2001 Jun 15;96(6):343-50 [11450586.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):772-8 [11380469.001]
  • [Cites] Eur J Dermatol. 2002 May-Jun;12(3):296-300 [11978579.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1530-3 [7932808.001]
  • [Cites] Cancer Treat Rev. 2005;31 Suppl 4:S29-37 [16360545.001]
  • [Cites] Ann Rheum Dis. 1997 Apr;56(4):224-5 [9165993.001]
  • [Cites] Kidney Int. 2006 Jul;70(1):16-23 [16760911.001]
  • [Cites] Arthritis Rheum. 2003 Aug;48(8):2246-55 [12905479.001]
  • [Cites] J Rheumatol. 2005 Nov;32(11):2144-9 [16265692.001]
  • [Cites] Nephrol Dial Transplant. 2006 Nov;21(11):3038-45 [16968717.001]
  • [Cites] Dermatology. 1999;199(2):183-4 [10559594.001]
  • [Cites] Rheum Dis Clin North Am. 1990 Feb;16(1):11-30 [2406802.001]
  • [Cites] J Clin Rheumatol. 2007 Aug;13(4):187-92 [17762451.001]
  • [Cites] Int Arch Allergy Appl Immunol. 1984;74(1):63-6 [6608501.001]
  • [Cites] Ann Rheum Dis. 2003 Aug;62(8):728-31 [12860727.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:407-23 [15561695.001]
  • [Cites] J Am Acad Dermatol. 2004 Aug;51(2 Suppl):S73-6 [15280817.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Sep;6(5):331-5 [12448236.001]
  • [Cites] Ann Surg. 1987 Jul;206(1):62-8 [3606232.001]
  • [Cites] Am J Nephrol. 1999;19(5):590-3 [10575189.001]
  • [Cites] Rheum Dis Clin North Am. 2005 Aug;31(3):465-81, vi [16084319.001]
  • [Cites] Int J Colorectal Dis. 1996;11(4):196-7 [8876279.001]
  • (PMID = 18368377.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


47. Kizer N, Zighelboim I, Rader JS: Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer. Int J Gynecol Cancer; 2009 Feb;19(2):237-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer.
  • BACKGROUND: The argon beam coagulation (ABC) is a safe and effective tool for surgical cytoreduction of metastatic ovarian carcinomas.
  • CASE: A 66-year-old woman with newly diagnosed advanced stage epithelial ovarian cancer underwent primary cytoreductive surgery involving ABC of tumor implants.
  • [MeSH-major] Abdominal Neoplasms / surgery. Adenocarcinoma / surgery. Gynecologic Surgical Procedures / adverse effects. Heart Arrest / etiology. Laser Coagulation / adverse effects. Ovarian Neoplasms / surgery


48. Abood G, Bowen M, Potkul R, Aranha G, Shoup M: Hepatic resection for recurrent metastatic ovarian cancer. Am J Surg; 2008 Mar;195(3):370-3; discussion 373
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for recurrent metastatic ovarian cancer.
  • BACKGROUND: The role for liver resection in metastatic ovarian cancer has not been defined.
  • The aim of the current study was to investigate the validity of hepatic resection as a treatment option in metastatic ovarian cancer.
  • METHODS: Retrospective review of a single institution's experience of patients undergoing hepatic resection for metastatic ovarian cancer from 1998-2006.
  • RESULTS: Ten patients underwent resection for metastatic ovarian cancer.
  • CONCLUSION: Liver resection for metastatic ovarian cancer is safe and is associated with long-term survival in some patients.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207130.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


49. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD: Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics; 2005 Apr;4(4):346-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.
  • Cancer can be defined as a deregulation or hyperactivity in the ongoing network of intracellular and extracellular signaling events.
  • Treatment of ovarian epithelial carcinoma almost always takes place in a metastatic setting since unfortunately the disease is often not detected until later stages.
  • Thus, in addition to elucidation of the molecular network within a tumor specimen, critical questions are to what extent do signaling changes occur upon metastasis and are there common pathway elements that arise in the metastatic microenvironment.
  • For individualized combinatorial therapy, ideal therapeutic selection based on proteomic mapping of phosphorylation end points may require evaluation of the patient's metastatic tissue.
  • [MeSH-major] Carcinoma / metabolism. Molecular Biology / methods. Ovarian Neoplasms / metabolism. Protein Array Analysis / methods. Proteomics / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671044.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA64602; United States / NCI NIH HHS / CA / P50CA83639A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides
  • [Number-of-references] 79
  •  go-up   go-down


50. Davidson B, Reich R, Trope CG, Wang TL, Shih IeM: New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histol Histopathol; 2010 12;25(12):1591-609
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New determinates of disease progression and outcome in metastatic ovarian carcinoma.
  • Ovarian cancer is the most lethal gynecologic malignancy.
  • This is attributed to frequent presentation at late stage, when the tumor has metastasized, as well as to development of chemotherapy resistance along tumor progression.
  • Patients with advanced-stage ovarian carcinoma have widespread intraperitoneal metastases, including the formation of malignant serous effusions within the peritoneal cavity.
  • Pleural effusions constitute the most frequent site of distant metastasis (FIGO stage IV disease).
  • Unlike the majority of solid tumors, particularly at the primary site, cancer cells in effusions are not amenable to surgical removal, and failure in their eradication is one of the main causes of treatment failure.
  • Our research in recent years has demonstrated that a large number of cancer-associated molecules are differentially expressed in effusions compared to primary carcinomas and solid metastases.
  • These observations are thought to be related to disease progression, as well as to the unique microenvironment of effusions, and may have impact on the selection of targeted therapy in this cancer.
  • This review discusses our recent observations with respect to the biology of ovarian carcinoma cells in effusions, and focuses on the clinical role of tumor-associated molecules at this anatomic site.
  • [MeSH-major] Ascitic Fluid / pathology. Biomarkers, Tumor / analysis. Carcinoma / pathology. Ovarian Neoplasms / pathology. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886439.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


51. Choi J, Credit K, Henderson K, Deverkadra R, He Z, Wiig H, Vanpelt H, Flessner MF: Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration. Clin Cancer Res; 2006 Mar 15;12(6):1906-12
Hazardous Substances Data Bank. Trastuzumab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration.
  • EXPERIMENTAL DESIGN: Human ovarian tumors (SKOV-3 and OVCAR-3) were established in the abdominal wall of athymic rats.
  • CONCLUSIONS: Reduction of collagen, but not hyaluronan, in the matrix of ovarian xenografts enhanced the transport of i.p. injected antibody.
  • [MeSH-major] Collagen / metabolism. Immunoglobulin G / therapeutic use. Immunotherapy / methods. Ovarian Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551876.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA085984; United States / NIDDK NIH HHS / DK / DK048479
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Immunoglobulin G; 9007-34-5 / Collagen; EC 3.2.1.35 / Hyaluronoglucosaminidase; EC 3.4.24.- / Collagenases; P188ANX8CK / Trastuzumab
  •  go-up   go-down


52. Schrader C, Keussen C, Bewig B, von Freier A, Lins M: Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res; 2005 Nov 16;10(11):498-501
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma.
  • INTRODUCTION: Paclitaxel (Taxol) is an anticancer agent used for the treatment of breast and ovarian cancer.
  • PATIENT: We report on a 58-years-old woman with a metastatic ovarian carcinoma who had chest pain, nausea and collapse during their first Taxol infusion.
  • RESULTS: The electrocardiography (ECG) showed a third-degree heart block and ST elevation in II, III and avF.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Carcinoma / drug therapy. Myocardial Ischemia / chemically induced. Myocardial Ischemia / physiopathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Paclitaxel / adverse effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354605.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents, Phytogenic; 9005-49-6 / Heparin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


53. Alcázar JL: Tumor angiogenesis assessed by three-dimensional power Doppler ultrasound in early, advanced and metastatic ovarian cancer: A preliminary study. Ultrasound Obstet Gynecol; 2006 Sep;28(3):325-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenesis assessed by three-dimensional power Doppler ultrasound in early, advanced and metastatic ovarian cancer: A preliminary study.
  • OBJECTIVE: To evaluate tumor vascularity by three-dimensional power Doppler ultrasound (3D-PDU) in early and advanced stage primary ovarian cancers and in metastatic tumors to the ovary.
  • PATIENTS AND METHODS: This was a retrospective analysis of clinical and sonographic data from 49 women with primary ovarian cancers or metastatic tumors to the ovary.
  • RESULTS: Among the 49 women, 10 had stage I primary cancers (five low-malignant potential tumors and five invasive tumors), 26 had advanced stage primary ovarian cancers and 13 had metastatic tumors to the ovary.
  • Mean VI and VFI were significantly higher in advanced stage tumors and metastatic tumors as compared with early stage tumors.
  • No differences in 3D-PDU indices were found between advanced stage and metastatic cancers.
  • CONCLUSIONS: Vascular indices derived from 3D-PDU tend to be higher in advanced stage and metastatic ovarian cancers as compared with early stage ovarian tumors.
  • [MeSH-major] Adnexal Diseases / ultrasonography. Imaging, Three-Dimensional / methods. Ovarian Neoplasms / blood supply

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 16906635.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Tserkezoglou A, Kontou S, Hadjieleftheriou G, Apostolikas N, Vassilomanolakis M, Sikiotis K, Salamalekis E, Tseke P, Magiakos G: Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results. Anticancer Res; 2006 May-Jun;26(3B):2339-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
  • BACKGROUND: The pre-operative diagnosis of primary and metastatic malignant ovarian tumors in patients treated for breast cancer is difficult.
  • The objective of this study was to analyze and compare the characteristics and outcome of women with a history of breast cancer in order to identify pre-operative markers useful in differential diagnosis and the role of surgery in their management.
  • MATERIALS AND METHODS: The medical records of 36 patients with a history of breast cancer, who had been operated on either for primary or metastatic cancer between 1987 and 2003, were reviewed retrospectively.
  • RESULTS: Twenty-seven patients had been diagnosed with primary epithelial ovarian cancer (POC) and nine had metastatic disease (MOC), resulting in a 3:1 ratio.
  • The median age of breast and ovarian cancer diagnosis was 45 and 56 years, respectively, and the median interval was 8 years.
  • BrCA mutation risk, as calculated with the BRCAPRO software program, was 41.8% and 9% in primary and metastatic tumors, respectively (p=0.0477).
  • Ovarian spread was not the only site of metastatic breast cancer in 55.5% of the MOC group, compared to 11% of the POC patients Disease was disseminated in the abdominal cavity at the time of diagnosis in both groups, however, 78% of patients had unilateral tumors in the POC group and bilateral disease in the MOC (p=0.0133).
  • Cytoreduction to less than 2 cm tumor diameter was feasible in 67% of primary and 44% of metastatic neoplasms.
  • In the follow-up period (12-204 months), the median survival was 10 months for patients with metastatic disease, compared to 33 months for those with primary tumors (p<0.05).
  • CONCLUSION: Small bilateral ovarian enlargements and minor serum elevation of CA 125 titers in patients with initial Stage IV breast cancer, suffering from multiple metastatic disease, are likely to illustrate MOC.
  • Unilateral ovarian mass and high serum levels of CA 125 in apparently disease-free patients with a positive family history and high prevelance of BRCA mutations are suggestive of primary tumors.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery


55. Skagias L, Ntinis A, Vasou O, Kondi-Pafiti A, Politi E: Ovarian carcinoma presenting with axillary lymph node metastasis: a case diagnosed by fine-needle aspiration and brief review of the literature. Diagn Cytopathol; 2008 Dec;36(12):891-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma presenting with axillary lymph node metastasis: a case diagnosed by fine-needle aspiration and brief review of the literature.
  • Ovarian carcinoma is a lethal disease and a main cause of morbidity and mortality among gynecological malignancies.
  • Metastatic ovarian carcinoma to the axillary node is an exceptionally infrequent pathological entity.
  • We report a case of ovarian carcinoma, which presented with axillary lymph node metastasis and review the previously documented cases.
  • A 63-year-old woman with a medical history of stage IIIb ovarian carcinoma was admitted to our hospital complaining of a mass in her right axilla.
  • Cytological examination revealed a poorly differentiated carcinoma with immunocytochemical features consistent with metastatic ovarian carcinoma.
  • This case illustrates a rare presentation of ovarian carcinoma and underlines the need to consider it in the differential diagnosis of axillary lesions.
  • [MeSH-major] Carcinoma / diagnosis. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18925569.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


56. Sala E, Priest AN, Kataoka M, Graves MJ, McLean MA, Joubert I, Griffiths JR, Crawford RA, Jimenez-Linan M, Earl HM, Brenton JD, Lomas DJ: Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development. Eur Radiol; 2010 Feb;20(2):491-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development.
  • This prospective study aims to evaluate the feasibility of DWI at 3 Tesla in patients with advanced ovarian cancer and investigate the differences in vascular signal fraction (VSF) and apparent diffusion coefficient (ADC) values between primary ovarian mass and metastatic disease.
  • Twenty patients with suspected advanced ovarian carcinoma were enrolled in the study.
  • High-resolution T2W FRFSE images were used to confirm the position of three marker lesions: primary ovarian mass, omental cake and peritoneal deposit.
  • Ovarian lesions showed the highest ADC values.
  • The mean ADC value for peritoneal deposits was significantly lower than for both ovarian lesions (p = 0.03) and omental cake (p = 0.03).
  • The VSF for omental cake was significantly higher than for ovarian lesions (p = 0.01) and peritoneal deposits (p = 0.04).
  • DWI in advanced ovarian cancer is feasible at 3 T.
  • There are significant differences in baseline ADC and VSF values between ovarian cancer, omental cake and peritoneal deposits that may explain the mixed treatment response that occurs at different disease sites.
  • [MeSH-major] Algorithms. Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2008 May;18(5):1058-64 [18193428.001]
  • [Cites] Eur Radiol. 2008 Apr;18(4):723-30 [17929022.001]
  • [Cites] Radiology. 1988 Aug;168(2):497-505 [3393671.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Apr;5(4):220-33 [18301415.001]
  • [Cites] Eur Radiol. 2009 Mar;19(3):745-60 [18839179.001]
  • [Cites] J Magn Reson Imaging. 2005 Aug;22(2):271-8 [16028258.001]
  • [Cites] MAGMA. 2004 Mar;16(4):182-93 [15007746.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):502-16 [12835670.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):583-92 [16862189.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4946-51 [17971592.001]
  • [Cites] Radiology. 2008 Dec;249(3):748-52 [19011179.001]
  • [Cites] Radiology. 1986 Nov;161(2):401-7 [3763909.001]
  • [Cites] Eur Radiol. 2008 Feb;18(2):384-9 [17917730.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 [17895480.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):71-8 [15538578.001]
  • [Cites] AJR Am J Roentgenol. 2008 Feb;190(2):481-8 [18212236.001]
  • [Cites] Eur Radiol. 2008 Jan;18(1):18-23 [17701040.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):1014-9 [11105044.001]
  • [Cites] J Magn Reson Imaging. 2007 Sep;26(3):682-7 [17729360.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):250-6 [11884782.001]
  • [Cites] Top Magn Reson Imaging. 2003 Aug;14(4):329-37 [14578777.001]
  • [Cites] Magn Reson Med Sci. 2007;6(4):211-24 [18239358.001]
  • (PMID = 19657643.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


57. Hoffman MS, Tebes SJ, Sayer RA, Lockhart J: Extended cytoreduction of intraabdominal metastatic ovarian cancer in the left upper quadrant utilizing en bloc resection. Am J Obstet Gynecol; 2007 Aug;197(2):209.e1-4; discussion 209.e4-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended cytoreduction of intraabdominal metastatic ovarian cancer in the left upper quadrant utilizing en bloc resection.
  • OBJECTIVE: The objective of the study was to describe the development of and experience with a technique for en bloc resection of left upper quadrant intraperitoneal metastatic ovarian cancer.
  • CONCLUSION: In highly selected patients undergoing cytoreductive surgery for ovarian cancer, en bloc resection of extensive left upper quadrant intraabdominal tumor may be a reasonable method for accomplishing optimal cytoreduction.
  • [MeSH-major] Abdominal Neoplasms / secondary. Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689654.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Burkart CM, Grisel JJ, Hom DB: Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope; 2008 Sep;118(9):1539-41
MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Diagnosis, Differential. Endoscopy. Female. Follow-Up Studies. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Rupture, Spontaneous. Vascular Endothelial Growth Factor A

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622319.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


59. Bosquet JG, Merideth MA, Podratz KC, Nagorney DM: Hepatic resection for metachronous metastases from ovarian carcinoma. HPB (Oxford); 2006;8(2):93-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for metachronous metastases from ovarian carcinoma.
  • However, the role of hepatic resection in combination with secondary cytoreduction for epithelial ovarian cancer is unclear.
  • Patients with recurrent ovarian cancer and metachronous intrahepatic metastases are often evaluated by a multidisciplinary team at the Mayo Clinic comprising pelvic and hepatobiliary surgeons for consideration of cytoreductive surgery.
  • The purpose of this report is to update the outcome of cytoreductive surgery including hepatic resection for patients with metastatic ovarian carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):273-80 [15491746.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1152-61 [15022281.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):278-87 [10053096.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):144-53 [10618617.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Gynecol Oncol. 1984 Jul;18(3):293-8 [6745731.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1606-14 [8635065.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):9-12 [8995540.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):45-51 [9234920.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1090-4 [11020885.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):171-5 [10926798.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):171-8 [9264559.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):504-12 [11733963.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Natl Cancer Inst Monogr. 1975 Oct;42:101-4 [1234624.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):16-21 [12694649.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):383-8 [14599870.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):269-76 [15650637.001]
  • (PMID = 18333253.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2131426
  •  go-up   go-down


60. Yeung KK, Coster E, Floris Vos AW, Van der Vijgh RK, Linsen MA, Wisselink W: Repeated arterial thrombosis as a complication of carboplatin-based chemotherapy. Vascular; 2006 Jan-Feb;14(1):51-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of a 57-year-old woman with repeated acute arterial thrombosis of the femoral arteries following intravenous carboplatin-based combination chemotherapy for metastatic ovarian carcinoma.
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Radiography. Recurrence

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849025.001).
  • [ISSN] 1708-5381
  • [Journal-full-title] Vascular
  • [ISO-abbreviation] Vascular
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


61. Klein RL, Brown AR, Gomez-Castro CM, Chambers SK, Cragun JM, Grasso-Lebeau L, Lang JE: Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review. J Cancer; 2010;1:27-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review.
  • Background. Primary ovarian carcinoma with metastasis to the breast is rare, with only 39 cases reported in the current literature.
  • Ovarian metastasis to the breast presenting as inflammatory breast carcinoma is even more infrequent, with only 6 cases reported.Case.
  • We present a patient who developed metastatic inflammatory cancer of the breast from a stage IIIC papillary serous ovarian adenocarcinoma approximately 1 year after the original diagnosis.
  • Pathologic analysis confirmed the origin of the tumor: a high-grade adenocarcinoma morphologically similar to the previously diagnosed ovarian cancer.
  • In addition, the tumor was strongly positive on immunohistochemistry for CA-125, identical to the ovarian primary.
  • Although ovarian metastasis to the breast presenting as inflammatory breast cancer is rare, it should be included in the differential diagnosis for any patient with a personal history of ovarian cancer.
  • Accurate differentiation is necessary because treatment differs significantly for patients with ovarian metastasis to the breast, as compared with patients with primary inflammatory breast cancer.
  • Ovarian metastasis to the breast confers a poor prognosis: patient survival ranged from 3 to 18 months, with a median survival of 6 months after the diagnosis of the breast metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842221.001).
  • [ISSN] 1837-9664
  • [Journal-full-title] Journal of Cancer
  • [ISO-abbreviation] J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2931350
  • [Keywords] NOTNLM ; breast cancer / breast cancer metastasis / inflammatory breast cancer / ovarian cancer / ovarian cancer metastasis
  •  go-up   go-down


62. dos Santos LA, Modica I, Flores RM, D'Angelica M, Aghajanian C, Chi DS, Abu-Rustum NR: En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report. Gynecol Oncol; 2006 Sep;102(3):596-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report.
  • INTRODUCTION: Multiple series have demonstrated the feasibility of full-thickness diaphragm resection for ovarian cancer metastatic to the diaphragm.
  • DISCUSSION: En bloc full-thickness diaphragm resection including a portion of lung tissue using the EndoGIA stapler is a safe, feasible, and effective method to optimize cytoreduction with disease-free margins in the context of invasive diaphragmatic ovarian cancer metastasis.
  • [MeSH-major] Diaphragm / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Ovarian Neoplasms / pathology. Thoracic Neoplasms / secondary


63. Wallace W, Mulholland K, Epanomeritakis E: Bleeding gastric varices--a rare complication of ovarian cancer. Int J Clin Pract; 2005 Jan;59(1):119-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleeding gastric varices--a rare complication of ovarian cancer.
  • Ovarian carcinoma recurring beyond 10 years, following primary treatment with no interval disease, is also a rare occurrence.
  • We report an unusual case of bleeding gastric varices secondary to splenic venous obstruction as a result of metastatic ovarian carcinoma.
  • This occurred 21 years following surgery and adjuvant chemotherapy for primary ovarian carcinoma.
  • To our knowledge, until now, there have been no reported cases of splenic venous hypertension due to ovarian carcinoma.
  • [MeSH-major] Esophageal and Gastric Varices / etiology. Gastrointestinal Hemorrhage / etiology. Hypertension, Portal / etiology. Ovarian Neoplasms / complications

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707476.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Lee SJ, Bae JH, Lee AW, Tong SY, Park YG, Park JS: Clinical characteristics of metastatic tumors to the ovaries. J Korean Med Sci; 2009 Feb;24(1):114-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of metastatic tumors to the ovaries.
  • Approximately 5-30% of the ovarian cancers are metastatic malignancies.
  • The prevalence of metastatic ovarian tumors varies with the incidence rates and spread patterns of primary malignancies.
  • We evaluated the prevalence, pre- and postoperative characteristics of metastatic ovarian cancer in Korean women.
  • We reviewed the records for 821 ovarian malignancies with pathological consultation from 1996-2006 and recorded patient demographical, radiological, histopathological, and survival data.
  • The study included 112 cases of histologically confirmed metastatic ovarian cancer.
  • Metastatic ovarian cancer accounted for 13.6% of all ovarian malignancy, primarily arising from the gastrointestinal tract.
  • The differential diagnosis of metastatic ovarian cancer can be problematic, so multiple diagnostic approaches are necessary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Apr;219(1):213-8 [11274559.001]
  • [Cites] Abdom Imaging. 2007 Nov;32(6):784-95 [17318680.001]
  • [Cites] Oncology. 2002;63(2):124-9 [12239446.001]
  • [Cites] J Ultrasound Med. 2003 Mar;22(3):243-7 [12636323.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):314-7 [12713997.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):397-401 [12893207.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):87-91 [15047218.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):477-82 [15297191.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):69-73 [15665686.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S99-111 [15492758.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3766-72 [15897574.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):235-41 [15982725.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):97-101 [16278010.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:132-8 [16515581.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):511 [16622117.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2339-44 [16821613.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):193-200 [17466362.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):78-82 [17049712.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):105-9 [11426970.001]
  • (PMID = 19270823.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ PMC2650975
  • [Keywords] NOTNLM ; Diagnostic Imaging / Metastasis / Ovary / Prevalence / Surgical Procedures
  •  go-up   go-down


65. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA: How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol; 2007 Oct;110(4):841-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The performance characteristics of the ACOG/SGO referral guidelines for detection of primary and metastatic ovarian cancer were calculated by using menopausal status, CA 125 level, imaging results, physical findings, and family history.
  • Forty-four percent (263/597) of postmenopausal women were diagnosed with ovarian cancer, whereas 20% (48/240) of premenopausal women had ovarian cancer.
  • Seventy-four percent of primary cancers were stage III or IV.
  • The referral guidelines performed better for late-stage than early-stage cancers in both sensitivity and positive predictive value, especially in postmenopausal women.
  • Although only 28 patients would not have been referred by the guidelines, the majority of these had early stage (I or II) disease.
  • CONCLUSION: The ACOG/SGO guidelines perform well in predicting advanced-stage ovarian cancer, probably owing to the nature of advanced-stage disease.
  • The guidelines perform poorly in identifying early-stage disease, especially in premenopausal women, primarily due to lack of early markers and signs of ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Practice Guidelines as Topic / standards. Referral and Consultation / standards


66. Zivanovic O, Barakat RR, Sabbatini PJ, Brown CL, Konner JA, Aghajanian CA, Abu-Rustum NR, Levine DA: Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up. Cancer; 2008 Jun 15;112(12):2690-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.
  • BACKGROUND: The aim was to determine the long-term outcome for patients with FIGO stage IV epithelial ovarian carcinoma (EOC) treated with intraperitoneal (IP) chemotherapy after second-look assessment.
  • METHODS: By using data from a retrospective cohort of 433 patients who received IP therapy after second-look assessment after primary surgery and initial systemic therapy for EOC between 1984 and 1998 at our institution, all FIGO stage IIIC and IV patients were identified.
  • RESULTS: Overall, 297 patients met study criteria (246 stage IIIC; 51 stage IV).
  • The median survival for patients with stage IV disease was 34 months compared with 42 months for patients with stage IIIC disease (P=.02).
  • The only significant predictor of overall survival in patients with stage IV disease was the presence of gross residual disease at initiation of IP therapy (P=.027).
  • When comparing stage IV patients with and without pleural effusions to all stage IIIC patients, there was a significant trend toward improved survival in the patients with pleural effusions only compared with other stage IV patients (P=.01).
  • When compared with similarly treated stage IIIC patients, stage IV patients with malignant pleural effusions appear to have a better outcome than those with other sites of metastasis.
  • Future prospective trials should evaluate the use of IP therapy for patients with stage IV EOC by virtue of malignant pleural effusions only who responded to initial systemic therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Ovarian Neoplasms / drug therapy


67. Fujiwara M, Taube J, Sharma M, McCalmont TH, Kim J: PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. J Cutan Pathol; 2010 Sep;37(9):938-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases.
  • BACKGROUND: The distinction of metastatic ovarian carcinoma from other metastatic carcinomas and primary adnexal lesions in the skin is often difficult.
  • PAX8 is a transcription factor that plays a critical role in development of the Müllerian system and has been shown to be a useful discriminatory marker between ovarian and breast carcinomas.
  • Identification of ovarian cutaneous metastases may be of benefit in patients with familial breast-ovarian carcinoma syndrome.
  • METHODS: PAX8 immunohistochemical analysis was performed on 24 cases of metastatic adenocarcinomas to the skin and compared with 7 cases of primary adnexal lesions and also compared with p63 immunohistochemical staining results.
  • Patients with metastatic adenocarcinomas had clinically documented primary malignancies, and patients with primary adnexal carcinomas had no known history of another adenocarcinoma.
  • RESULTS: Cutaneous ovarian and renal cell carcinoma metastases (2/2 and 8/8, respectively) showed positive nuclear expression of PAX8.
  • The p63 expression profile supported the distinction between adnexal and metastatic adenocarcinomas.
  • CONCLUSIONS: Although cutaneous ovarian metastasis is a rare phenomenon, the prognosis is extremely poor.
  • PAX8 expression is a useful marker that effectively discriminated metastatic ovarian carcinomas from metastatic breast carcinomas and primary adnexal tumors.
  • [MeSH-major] Neoplasms, Adnexal and Skin Appendage / diagnosis. Ovarian Neoplasms / diagnosis. Paired Box Transcription Factors / metabolism. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492080.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


68. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, Fishman DA: LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol; 2009 Jan;112(1):215-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LPA receptor 2 mediates LPA-induced endometrial cancer invasion.
  • OBJECTIVE: We have previously shown that lysophosphatidic acid (LPA) promotes the ovarian cancer metastatic cascade.
  • In this study, we evaluated the role of LPA on endometrial cancer invasion.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019417.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA125227-01; United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / R21 CA125227-01; United States / NCI NIH HHS / CA / U01 CA85133
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lysophospholipids; 0 / RNA, Small Interfering; 0 / Receptors, Lysophosphatidic Acid; 22002-87-5 / lysophosphatidic acid; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


69. Nojkov B, Cappell MS: Safety and efficacy of ERCP after recent myocardial infarction or unstable angina. Gastrointest Endosc; 2010 Oct;72(4):870-80
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven patients subsequently did well (mean hospital discharge 6.5 days after ERCP); 1 patient with metastatic ovarian cancer remained ventilator dependent, and another patient with multiple comorbidities had a fatal pulmonary embolus 10 days after ERCP.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20883868.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


70. Ohde Y, Nakagawa K, Okumura T, Kondo H: Spontaneous pulmonary torsion secondary to pseudo-Meigs' syndrome. Interact Cardiovasc Thorac Surg; 2005 Feb;4(1):59-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 45-year-old woman with colonic cancer and metastatic ovarian cancer was suffering from dyspnea.
  • The pleural effusion had never recurred after resection of the metastatic ovary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670356.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Richard SD, Sukumvanich P, Lesnock JL, McBee WC, Beriwal S, Edwards RP, Zorn KK, Krivak TC: Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels. Int J Gynecol Cancer; 2010 Aug;20(6):932-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hypothesize that patients undergoing IP chemotherapy may have elevated CA125 values when compared with patients receiving intravenous (IV) chemotherapy.
  • METHODS: From February 2006 to July 2007, optimally debulked patients with stage III and stage IV ovarian carcinoma from a single institution were offered an outpatient IV/IP chemotherapy regimen modified from Gynecologic Oncology Group 172.
  • They were matched to a cohort of similar patients who received IV paclitaxel and carboplatin.
  • RESULTS: Fifty patients received the standard IV regimen, and 38 patients completed the modified IV/IP regimen.
  • After 6 cycles of therapy, 68.4% (26/38) of the IP cohort had a normal CA125 level before IP catheter removal compared with 78% (39/50) in the IV chemotherapy cohort (P = 0.44).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. CA-125 Antigen / blood. Catheterization / adverse effects. Ovarian Neoplasms / blood. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683398.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


72. Karam AK, Stempel M, Barakat RR, Morrow M, Gemignani ML: Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass. Gynecol Oncol; 2009 Mar;112(3):490-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
  • OBJECTIVE: A breast and/or axillary mass in a patient with epithelial ovarian cancer (EOC) may be due to an EOC breast metastasis or a second primary breast cancer.
  • METHODS: Between 1/90 and 10/07, 29 women with epithelial EOC presented with a breast or axillary mass, including 10 patients with EOC metastatic to the breast and/or axilla and 19 patients with a second primary breast cancer following their original EOC diagnosis.
  • RESULTS: The mean EOC disease-free survival (DFS) was 14.9 mo versus 77.4 mo (P<0.001) for patients with recurrent epithelial ovarian cancer metastatic to the breast and/or axilla and patients with a second primary breast cancer, respectively.
  • Similarly, the mean interval between diagnosis of EOC and the breast and/or axillary event was 31.2 mo versus 70.7 mo for those patients who had metastatic recurrent EOC and those patients with breast cancer (P=0.02).
  • Patients with a second primary breast cancer were more likely to be diagnosed on mammogram and have a family history of breast and ovarian carcinoma than patients with metastatic EOC to the breast and/or axilla (14/19 [73.7%] versus 2/9 [22.8%], P=0.02; and 12/18 [66.7%] versus 2/10 [20%], P=0.05, respectively).
  • Median overall survival for patients with EOC metastasis was 26 mo but was not yet reached for those patients with a second primary breast cancer.
  • On univariate analysis, an ovarian cancer DFS of 12 mo or more and the performance of breast/axillary surgery were associated with a significantly longer overall survival (P=0.01 and 0.02, respectively), whereas an elevated CA125 level at the time of the breast/axilla event and the presence of EOC metastases to the breast and axilla were significant negative predictors of survival (P=0.01 and 0.05, respectively).
  • CONCLUSION: The interval between EOC diagnosis and the breast and/or axilla event, an elevated CA125 level, and a family history of breast and/or ovarian cancer may help differentiate patients with metastatic EOC to the breast and/or axilla from those patients with a second primary breast cancer.
  • The presence of a metastatic EOC portends a poor prognosis.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / secondary. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease-Free Survival. Epithelial Cells / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies


73. Paianidi IuG, Sel'chuk VIu, Zhordania KI, Anurova OA, Chemeris GIu, Zakharova TI, Savelov NA, Moroz EA: [Female genital tract polyneoplasia: primary multiple neoplasms or metastases?]. Arkh Patol; 2006 Jul-Aug;68(4):16-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The analysis of 49 cases of synchronous and metachronous malignant mucinous tumors of the colon (rectum) and ovaries in the patients treated in 1990 to 2004 again has confirmed the data that metastatic ovarian cancer occurs from a primary focus in the colorectal region.
  • Immunohistochemical studies (using cytokeratin 7 and cytokeratin 20) may be used in the differential diagnosis of ovarian mucinous ovarian carcinoma from metastatic colonic mucinous tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Colonic Neoplasms / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986489.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


74. Le T, Faught W, Hopkins L, Fung Kee Fung M: Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):770-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer.
  • The aim of this article was to review the experience with neoadjuvant chemotherapy and interval surgical debulking in patients with metastatic epithelial ovarian cancer.
  • Neoadjuvant chemotherapy with interval debulking surgery appeared to be safe and feasible in patients with metastatic epithelial ovarian carcinoma.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174222.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Skarf LM, Dezube BJ, Bryan B, Berkenblit A: Ovarian carcinoma with thyroid metastases causing clinical hypothyroidism: a case report. Gynecol Oncol; 2006 Aug;102(2):394-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma with thyroid metastases causing clinical hypothyroidism: a case report.
  • BACKGROUND: Ovarian cancer is known to metastasize to the thyroid gland.
  • Despite an incidence of ovarian metastasis to the thyroid of 3-15%, clinical hypothyroidism resulting from such metastasis has not yet been reported.
  • We present a case of metastatic ovarian cancer to the thyroid resulting in clinical hypothyroidism.
  • CASE: A 55-year-old woman with recurrent papillary adenocarcinoma of the ovary presented with fatigue, abdominal distention, lymphedema, and depression.
  • Thyroid stimulating hormone was markedly elevated, and thyroid biopsy demonstrated bilateral metastatic ovarian carcinoma.
  • CONCLUSION: Although uncommon, metastatic disease to the thyroid should be considered when evaluating a patient with advanced ovarian cancer and clinical hypothyroidism.
  • [MeSH-major] Hypothyroidism / etiology. Ovarian Neoplasms / pathology. Thyroid Neoplasms / complications. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564565.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Evans CL, Rizvi I, Hasan T, de Boer JF: In vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging. Opt Express; 2009 May 25;17(11):8892-906
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging.
  • In vitro three-dimensional models for metastatic ovarian cancer have been useful for recapitulating the human disease.
  • The development of a time-lapse OCT system, capable of automated, multidimensional acquisition, further provided insights into the growth and chemotherapeutic response of ovarian cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):266-76 [12001988.001]
  • [Cites] Arch Ophthalmol. 2005 Dec;123(12):1715-20 [16344444.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1516-24 [16234565.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Opt Lett. 2005 Apr 1;30(7):747-9 [15832926.001]
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):C1109-23 [9357753.001]
  • [Cites] Cytometry. 1997 Jan 1;27(1):1-20 [9000580.001]
  • [Cites] J Biomed Opt. 2007 Jul-Aug;12(4):041205 [17867794.001]
  • [Cites] Nat Methods. 2007 Apr;4(4):359-65 [17396127.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2006 Sep-Oct;42(8-9):242-7 [17163781.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:287-309 [16824016.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):467-74 [10744824.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):7-12 [11208708.001]
  • [Cites] J Am Coll Cardiol. 2002 Feb 20;39(4):604-9 [11849858.001]
  • [Cites] Opt Lett. 2006 Apr 15;31(8):1079-81 [16625909.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1361-7 [14595364.001]
  • [Cites] Phys Rev Lett. 2004 Mar 26;92(12):123905 [15089675.001]
  • [Cites] Cancer Res. 1986 Apr;46(4 Pt 2):1972-9 [3512077.001]
  • [Cites] Science. 1990 Apr 6;248(4951):73-6 [2321027.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):619-26 [8106557.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):588-95 [8938139.001]
  • (PMID = 19466138.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / R01 RR019768; United States / NIAMS NIH HHS / AR / R01 AR040352; United States / NIAMS NIH HHS / AR / AR040352-09; United States / NIAMS NIH HHS / AR / R01 AR040352-09; United States / NCRR NIH HHS / RR / RR019768-01; United States / NCRR NIH HHS / RR / R01 RR019768-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS180857; NLM/ PMC2836890
  •  go-up   go-down


77. See HT, Thomas DA, Bueso-Ramos C, Kavanagh J: Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:236-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer.
  • We report a patient with metastatic ovarian carcinoma treated with carboplatin and paclitaxel, who developed secondary acute erythroid leukemia.
  • The overall survival of patients with stage III and IV ovarian cancer has increased in the past decade.
  • The incidence and outcome of secondary leukemia in the setting of active ovarian carcinoma is reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Erythroblastic, Acute / chemically induced. Liver Neoplasms / therapy. Neoplasms, Glandular and Epithelial / therapy. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515597.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BG3F62OND5 / Carboplatin; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; P88XT4IS4D / Paclitaxel; ZRP63D75JW / Idarubicin
  •  go-up   go-down


78. Khan S, Taylor JL, Rinker-Schaeffer CW: Disrupting ovarian cancer metastatic colonization: insights from metastasis suppressor studies. J Oncol; 2010;2010:286925
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disrupting ovarian cancer metastatic colonization: insights from metastasis suppressor studies.
  • Ovarian cancer affects approximately 25,000 women in the United States each year and remains one of the most lethal female malignancies.
  • Improved therapies require mechanistic information about the process of metastatic colonization, the final step in metastasis, in which cancer cells undergo progressive growth at secondary sites.
  • Studies of metastasis suppressors are providing insights into events controlling metastatic colonization.
  • This paper reviews our laboratory's approach to the identification, characterization, and functional testing of the JNKK1/MKK4 metastasis suppressor in ovarian cancer metastatic colonization.
  • Specifically, we demonstrate that interaction of ovarian caner cells with the omental microenvironment activates JNKK1/MKK4 resulting in decreased proliferation without affecting apoptosis.
  • It is our goal to provide this work as a usable paradigm that will enable others to study metastasis suppressors in clinical and experimental ovarian cancer metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5400-2 [1394145.001]
  • [Cites] Res Immunol. 1992 May;143(4):401-9 [1518954.001]
  • [Cites] Arch Histol Cytol. 1990;53 Suppl:165-77 [2252628.001]
  • [Cites] Semin Oncol. 1989 Apr;16(2):91-105 [2652316.001]
  • [Cites] J Natl Cancer Inst. 1989 May 3;81(9):648-9 [2709420.001]
  • [Cites] Science. 1984 Jun 1;224(4652):998-1001 [6719130.001]
  • [Cites] Anat Rec. 1995 Feb;241(2):163-74 [7710133.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):687-92 [8425204.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):804-6 [8657286.001]
  • [Cites] Science. 1998 Apr 24;280(5363):599-602 [9554853.001]
  • [Cites] Biochem Soc Symp. 1999;64:1-12 [10207617.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5483-7 [10554023.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):807-69 [11274345.001]
  • [Cites] Respirology. 2002 Sep;7(3):171-91 [12153683.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6717-23 [12438272.001]
  • [Cites] Cancer Lett. 2003 Jul 30;198(1):1-20 [12893425.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):9-16 [14592528.001]
  • [Cites] Cell Cycle. 2005 Jan;4(1):57-62 [15611649.001]
  • [Cites] Anat Embryol (Berl). 2005 Feb;209(3):251-61 [15662530.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2264-70 [16489030.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3882-9 [16818682.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1739-52 [17071597.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):67-73 [18049862.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2166-75 [18381422.001]
  • [Cites] Clin Exp Metastasis. 2009;26(1):67-76 [18516689.001]
  • [Cites] Cancer Lett. 2008 Dec 8;272(1):12-22 [18572308.001]
  • [Cites] Cancer Microenviron. 2008 Dec;1(1):1-11 [19308680.001]
  • (PMID = 20300552.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009566
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2838371
  •  go-up   go-down


79. Sasaki H, Ohara N, Minamikawa T, Umeda M, Komori T, Kojima N, Takemura N, Morita H, Sugihara R, Enoki E, Itoh T: Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). Kobe J Med Sci; 2008;54(3):E174-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report).
  • Most metastatic tumors have the propensity for involving the mandible rather than the oral soft tissues.
  • Herein, we describe an unusual case of ovarian mucinous cystadenocarcinoma that metastasized to the mandibular gingiva as an initial manifestation.
  • There is little information regarding metastatic ovarian cancer to the oral cavity.
  • A biopsy taken from the gingiva showed mucinous adenocarcinoma, indicating the gingival metastasis of undiscovered primary cancer.
  • A positron emission tomography and computed tomography using 18F-fluorodeoxyglucose depicted an ovarian tumor with multiple pelvic and paraaortic lymph node swellings.
  • A magnetic resonance imaging (MRI) clearly demonstrated the presence of an ovarian cancer.
  • Based on the imaging studies, the diagnosis of the gingival metastasis of an ovarian cancer was suspected.
  • The histology of surgical specimen confirmed the gingival metastasis of ovarian mucinous adenocarcinoma.
  • This case emphasizes that although rare, metastatic ovarian cancer to the gingiva should be included in the differential diagnosis of tumors in the oral cavity.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Gingival Neoplasms / secondary. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246966.001).
  • [ISSN] 1883-0498
  • [Journal-full-title] The Kobe journal of medical sciences
  • [ISO-abbreviation] Kobe J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


80. Oremek G, Sauer-Eppel H, Klepzig M: Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas. Anticancer Res; 2007 Jul-Aug;27(4A):1961-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was the investigation of the diagnostic value of the amino-terminal propeptide of type I collagen (P1NP) and the tumour markers, CA 15-3 and CA 125, in patients with breast and ovarian cancer.
  • Baseline serum samples of 66 patients with metastatic breast cancer and 34 patients with metastatic ovarian cancer under chemotherapy were investigated.
  • These markers are abnormally raised in the blood of patients with metastatic bone disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Collagen Type I / blood. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649805.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Collagen Type I; 0 / Mucin-1
  •  go-up   go-down


81. Gurbuz A, Kir G, Karateke A, Haliloglu B, Kabaca C: Metastatic ovarian carcinoma one year after surgical removal of colon carcinoma during pregnancy: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:330-3
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ovarian carcinoma one year after surgical removal of colon carcinoma during pregnancy: a case report.
  • Colorectal carcinoma during pregnancy is a very rare event.
  • We presented a woman with metachronous metastatic ovarian tumor existing 1 year after surgical removal of perforated sigmoid colon carcinoma encountered during cesarean section of woman of 36-week gestation for fetal distress.
  • Pregnant women with suspicious abdominal mass should be evaluated for a possible colorectal carcinoma even in the absence of any other gastrointestinal symptoms associated with it and undergo rectal examination and sigmoidoscopy.
  • In addition, as synchronous and metachronous ovarian metastases are common in these patients, ovaries must be evaluated carefully by bisection during operation for possible metastasis, and in women who do not have a desire for fertility, prophylactic oophorectomy seems an appropriate treatment modality for resecting synchronous metastasis and preventing future metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Intestinal Perforation / etiology. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515616.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


82. Bryan DN, Radbod R, Berek JS: An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):125-34
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer.
  • The objective of this study was to compare the treatment outcomes of surgical versus chemotherapeutic interventions for the management of intestinal obstruction secondary to metastatic epithelial ovarian cancer.
  • A retrospective analysis of 39 patients with epithelial ovarian cancer who had 98 events of intestinal obstruction was performed.
  • A medical records review of patients treated for advanced ovarian cancer from 1973 to 2003 was conducted.
  • Mean time from diagnosis of cancer to first obstruction was 38 months (range, 7-234 months).
  • Of 39 patients with obstruction, 5% were stage I, 2% stage II, 85% stage III, and 8% stage IV.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Palliative Care. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445622.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G: Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol; 2010 Nov;21(11):2201-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.
  • BACKGROUND: Ovarian cancer is the leading cause of death in women with gynecological malignancies.
  • Brain metastases are considered an uncommon metastatic site.
  • PATIENTS AND METHODS: A multicenter retrospective chart review was carried out including all patients with histologically confirmed ovarian cancer from six different German hospitals from 1981 to 2008.
  • Overall, 4277 cases of patients with ovarian cancer were screened and patients with brain metastasis were identified and analyzed regarding various clinical variables and survival.
  • CONCLUSIONS: Platinum sensitivity is the most important prognostic factor in patients with ovarian cancer metastatic to the brain.
  • This novel finding should be considered in the strategy of multimodal therapy for brain metastases in ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Clin Oncol. 2011 Jan;8(1):2 [21218524.001]
  • (PMID = 20439341.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


84. Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, Chambers SK: Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor. Neoplasia; 2009 Feb;11(2):136-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.
  • Coexpression of the macrophage colony-stimulating factor (CSF-1) and its receptor (CSF-1R) in metastatic ovarian cancer specimens is a predictor of poor outcome in epithelial ovarian cancer.
  • This suggests that an autocrine loop is produced by which ovarian tumors can secrete CSF-1 stimulating the CSF-1R resulting in a more aggressive phenotype.
  • Our current work sought to validate this autocrine stimulation model using stable transfection of a 4-kb CSF-1 construct into otherwise nonvirulent Bix3 ovarian cancer cells.
  • [MeSH-major] Cell Transformation, Neoplastic. Macrophage Colony-Stimulating Factor / genetics. Macrophage Colony-Stimulating Factor / metabolism. Neoplasm Metastasis / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):159-64 [2663797.001]
  • [Cites] Cancer Lett. 1987 Dec;38(1-2):137-47 [3690504.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):990-6 [1825026.001]
  • [Cites] Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1356-62 [1957862.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3610-4 [1617632.001]
  • [Cites] Am J Obstet Gynecol. 1993 Feb;168(2):520-7 [8438921.001]
  • [Cites] Cell. 1993 Mar 26;72(6):903-17 [8384533.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2513-21 [8388317.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2553-9 [8495419.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1107-17 [7505203.001]
  • [Cites] Br J Cancer. 1994 Feb;69(2):342-6 [8297732.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3696-9 [8033085.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):529-42 [7845678.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1578-85 [7882368.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4366-9 [8813126.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5704-12 [8971179.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):999-1007 [9815777.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3762-71 [15867372.001]
  • [Cites] Med Res Rev. 2007 Mar;27(2):149-76 [16888756.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jul-Aug;17(4):784-8 [17343607.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):147-52 [18185580.001]
  • [Cites] Mini Rev Med Chem. 2008 Mar;8(3):248-55 [18336345.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3607-16 [18519795.001]
  • [Cites] Mol Cancer Res. 2008 Aug;6(8):1375-84 [18708368.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):194-200 [11161859.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):727-40 [11257139.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):173-7 [14734466.001]
  • [Cites] Am J Obstet Gynecol. 2004 Apr;190(4):974-85 [15118624.001]
  • [Cites] Biochemistry. 1979 Nov 27;18(24):5294-9 [518835.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3668-76 [4016745.001]
  • [Cites] Science. 1987 Mar 20;235(4795):1504-8 [3493529.001]
  • [Cites] Am J Pathol. 1990 Jul;137(1):135-47 [1695482.001]
  • (PMID = 19177198.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oligonucleotides, Antisense; 81627-83-0 / Macrophage Colony-Stimulating Factor; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC2631138
  •  go-up   go-down


85. Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, Stack MS: Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res; 2009 Sep 1;69(17):7121-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination.
  • An early event in the metastasis of epithelial ovarian carcinoma is shedding of cells from the primary tumor into the peritoneal cavity followed by diffuse i.p. seeding of secondary lesions.
  • Anchorage-independent metastatic cells are present as both single cells and multicellular aggregates (MCA), the latter of which adhere to and disaggregate on human mesothelial cell monolayers, subsequently forming invasive foci.
  • Although this unique metastatic mechanism presents a distinct set of therapeutic challenges, factors that regulate MCA formation and dissemination have not been extensively evaluated.
  • Proteolytic activity is important at multiple stages in i.p. metastasis, catalyzing migration through the mesothelial monolayer and invasion of the collagen-rich submesothelial matrix to anchor secondary lesions, and acquisition of membrane type 1 matrix metalloproteinase (MT1-MMP; MMP-14) expression promotes a collagen-invasive phenotype in ovarian carcinoma.
  • MT1-MMP is regulated posttranslationally through multiple mechanisms including phosphorylation of its cytoplasmic tail, and the current data using ovarian cancer cells expressing wild-type, phosphomimetic (T567E-MT1-MMP), and phosphodefective (T567A-MT1-MMP) MT1-MMP show that MT1-MMP promotes MCA formation.
  • Analysis of human ovarian tumors shows elevated MT1-MMP in metastases relative to paired primary tumors.
  • These data suggest that MT1-MMP activity may be key to ovarian carcinoma metastatic success by promoting both formation and dissemination of MCAs.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Jun 12;149(6):1309-23 [10851027.001]
  • [Cites] J Biol Chem. 2009 Jul 24;284(30):19791-9 [19458085.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):517-24 [11293899.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4837-41 [11406560.001]
  • [Cites] J Soc Gynecol Investig. 2001 Sep-Oct;8(5):299-304 [11677151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13693-8 [11698655.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1345-56 [11756481.001]
  • [Cites] Nat Cell Biol. 2002 Aug;4(8):632-8 [12134161.001]
  • [Cites] Biotechnol Bioeng. 2003 Jul 20;83(2):173-80 [12768623.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):170-81 [15047232.001]
  • [Cites] Am J Obstet Gynecol. 1974 Aug 1;119(7):991-4 [4276313.001]
  • [Cites] J Pathol. 1983 Mar;139(3):337-47 [6834177.001]
  • [Cites] Exp Cell Res. 1985 Oct;160(2):499-513 [3899694.001]
  • [Cites] Clin Exp Metastasis. 1987 Apr-Jun;5(2):181-97 [3297449.001]
  • [Cites] Kidney Int. 1990 Jun;37(6):1563-70 [2362409.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):5028-32 [8402695.001]
  • [Cites] Lab Invest. 1994 Mar;70(3):333-8 [8145527.001]
  • [Cites] Curr Opin Genet Dev. 1994 Feb;4(1):82-9 [8193545.001]
  • [Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] J Biol Chem. 1996 Jul 19;271(29):17119-23 [8663332.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2446-51 [8999957.001]
  • [Cites] Eur J Biochem. 1997 Dec 15;250(3):751-7 [9461298.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):155-65 [9490275.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1635-41 [10197640.001]
  • [Cites] Cell. 1999 Oct 1;99(1):81-92 [10520996.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):316-9 [16240401.001]
  • [Cites] Semin Reprod Med. 2006 Sep;24(4):270-82 [16944424.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4924-31 [17158885.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2030-9 [17332331.001]
  • [Cites] Ann Oncol. 2007 May;18(5):945-9 [17298959.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1463-72 [17546601.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):358-67 [17609667.001]
  • [Cites] Mol Carcinog. 2007 Oct;46(10):872-85 [17455221.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):24-33 [17702616.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):385-94 [18036641.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):643-55 [18398687.001]
  • [Cites] Carcinogenesis. 2008 Aug;29(8):1655-64 [18621744.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7247-9 [18794108.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):319-24 [18976802.001]
  • [Cites] Mol Cancer Res. 2009 Jun;7(6):809-20 [19509114.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1279-88 [11290546.001]
  • (PMID = 19706774.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109545-04; United States / NCI NIH HHS / CA / CA86984; United States / NCI NIH HHS / CA / R01 CA086984-09; United States / NCI NIH HHS / CA / CA086984-09S1; United States / NCI NIH HHS / CA / R01 CA086984; United States / NCI NIH HHS / CA / R01 CA086984-08S1; United States / NCI NIH HHS / CA / CA86984-S1; United States / NCI NIH HHS / CA / CA109545; United States / NCI NIH HHS / CA / R01 CA109545-03; United States / NCI NIH HHS / CA / CA086984-08; United States / NCI NIH HHS / CA / CA109545-03; United States / NCI NIH HHS / CA / R01 CA109545; United States / NCI NIH HHS / CA / R01 CA086984-08; United States / NCI NIH HHS / CA / R01 CA086984-09S1; United States / NCI NIH HHS / CA / CA086984-08S1; United States / NCI NIH HHS / CA / CA086984-09; United States / NCI NIH HHS / CA / CA109545-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS128017; NLM/ PMC2737080
  •  go-up   go-down


86. Sengupta S, Michener CM, Escobar P, Belinson J, Ganapathi R: Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion. Gynecol Oncol; 2008 May;109(2):226-33
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.
  • OBJECTIVES: To identify proteins unique to metastatic ovarian cancer and test their potential involvement in cell adhesion.
  • METHODS: We purified plasma membrane from paired metastatic and primary tumor tissues from patients with stage IIIC ovarian cancer.
  • The role of one of the identified proteins, ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1) in cell adhesion was determined in the presence of LPA using both over-expression and down regulation approaches.
  • RESULTS: We identified a differentially expressed 29 kDa protein as OCIAD1 over-expressed in metastatic tissues, when compared to primary tumor tissues.
  • OCIAD1 over-expression in HEY ovarian cancer cells increased LPA-induced, but not basal level cell adhesion to extracellular matrix proteins collagen I and laminin 10/11.
  • CONCLUSIONS: This is the first report that OCIAD1 is over-expressed in metastatic ovarian cancer tissues.
  • The effect of OCIAD1 on cell adhesion may be related to its function in ovarian cancer.
  • Failure of paclitaxel to affect ovarian cancer cell adhesion in presence of OCIAD1 raises the possibility of OCIAD1's role in tumor metastasis.
  • Ongoing studies using a mouse orthotopic LPA-dependent ovarian cancer metastasis model are focused on strategies to inhibit the potential role of OCIAD1 in tumor metastasis.
  • [MeSH-major] Adenocarcinoma / physiopathology. Neoplasm Proteins / metabolism. Ovarian Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328549.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Collagen Type I; 0 / Laminin; 0 / Lysophospholipids; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / ovarian cancer immuno-reactive antigen domain containing 1, human; 22002-87-5 / lysophosphatidic acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


87. Navarro-Alvarez N, Kondo E, Kawamoto H, Hassan W, Yuasa T, Kubota Y, Seita M, Nakahara H, Hayashi T, Nishikawa Y, Hassan RA, Javed SM, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N, Soto-Gutierrez A: Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant; 2010;19(6):865-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been proposed in human colorectal cancers (CRC) a minority subset of cancer cells within tumors able to initiate tumor growth, defined as cancer stem cells (CSC).
  • Solid human primary colonic and its ovarian metastatic cancer tissues were collected from fresh surgical samples and subsequent xenografts were established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.
  • Surface markers of progenitor cells were immunophenotypically analyzed, and expression of stem cell and cancer-related genes was characterized.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Rev Cytol. 1998;177:1-56 [9378615.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):35-44 [9036867.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):275-81 [15791572.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Mol Cell. 2005 Dec 22;20(6):845-54 [16359901.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85 [17179479.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):761-8 [17955491.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):56-64 [18166348.001]
  • [Cites] Gut. 2008 Apr;57(4):538-48 [18334662.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Cancer Sci. 2008 May;99(5):979-85 [18294281.001]
  • [Cites] Cell Transplant. 2008;17(1-2):19-25 [18468231.001]
  • [Cites] Cell Transplant. 2008;17(1-2):27-33 [18468232.001]
  • [Cites] Br J Cancer. 2008 May 20;98(10):1614-8 [18475294.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Oncology. 2008;74(1-2):17-24 [18536526.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4219-24 [18594003.001]
  • [Cites] PLoS One. 2008;3(7):e2637 [18612434.001]
  • [Cites] PLoS One. 2008;3(10):e3544 [18958156.001]
  • [Cites] Cell Transplant. 2010;19(5):509-23 [20053319.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2678-90 [10541554.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):961-71 [11040183.001]
  • [Cites] Nat Med. 2001 Feb;7(2):186-91 [11175849.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1372-6 [11355949.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2239-48 [11733373.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50 [12598651.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):7942-9 [12970742.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Dec;11(4):306-10 [14663355.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):217-24 [14732230.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1392-9 [15205684.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):114-21 [3812871.001]
  • [Cites] Semin Diagn Pathol. 1991 Nov;8(4):250-76 [1759059.001]
  • [Cites] Cell. 1994 Oct 21;79(2):185-8 [7525076.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):586-92 [7677172.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • (PMID = 20587145.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK083556-02; United States / NIDDK NIH HHS / DK / K99 DK083556; United States / NIDDK NIH HHS / DK / K99 DK083556-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Glycoproteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Peptides
  • [Other-IDs] NLM/ NIHMS227250; NLM/ PMC2957535
  •  go-up   go-down


88. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR: Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle; 2010 Jan 15;9(2):260-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.
  • Current therapies for metastatic ovarian carcinoma are based on surgical debulking followed by chemotherapy.
  • After more than three decades implementing treatments that selectively target the tumor cell, the 5-year survival rate for metastatic ovarian cancer patients is still lower than 30%.
  • Recently, leukocytes in the ovarian cancer microenvironment such as regulatory T cells and immature pro-angiogenic/tolerogenic myeloid cells have been demonstrated to play a fundamental role in tumor progression.
  • This review focuses on our recent understanding of the potential of eliminating and/or modulating the phenotype of these leukocytes in vivo and in situ as a novel intervention to complement standard ovarian cancer treatments.
  • The significant effects of targeting these crucial microenvironmental players on cancer vascularization, local tumor growth, distal metastatic spreading and spontaneous anti-tumor immune responses are discussed.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Jan 15;105(2):679-81 [15358628.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):207-8 [15766657.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1182-7 [15785750.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Am J Reprod Immunol. 2005 Dec;54(6):369-77 [16305662.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):871-81 [16606666.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):635-42 [16627987.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):159-70 [16904613.001]
  • [Cites] Eur J Surg Oncol. 2006 Oct;32(8):875-86 [16704916.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2691-702 [17101732.001]
  • [Cites] Adv Exp Med Biol. 2007;590:185-93 [17191386.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):425; author reply 426 [17210725.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1083-8 [17317815.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):876-83 [17327609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 [17360651.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4783-9 [17510407.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8900-5 [17875732.001]
  • [Cites] Cell. 2007 Nov 2;131(3):463-75 [17981115.001]
  • [Cites] Trends Immunol. 2007 Dec;28(12):519-24 [17981504.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):903-7 [18026089.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):825-31 [18064003.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3372-9 [18519766.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] J Exp Med. 2008 Sep 1;205(9):2125-38 [18725522.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7684-91 [18768667.001]
  • [Cites] Cell Cycle. 2008 Aug 15;7(16):2452-5 [18719382.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):2974-7 [18838866.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7667-73 [19047092.001]
  • [Cites] Mol Immunol. 2008 Dec;46(2):258-68 [18824264.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:1761-70 [19273160.001]
  • [Cites] Cell Cycle. 2009 Apr 1;8(7):970-6 [19270527.001]
  • [Cites] Expert Opin Biol Ther. 2009 Jun;9(6):677-88 [19456205.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1930-4 [19448397.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1818-9 [19471123.001]
  • [Cites] J Transl Med. 2009;7:49 [19545375.001]
  • [Cites] Blood. 2009 Jul 23;114(4):901-14 [19383967.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6331-8 [19602595.001]
  • [Cites] J Clin Invest. 2009 Aug;119(8):2231-44 [19620771.001]
  • [Cites] Curr Opin Pharmacol. 2009 Aug;9(4):470-81 [19616475.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7329-37 [19738057.001]
  • [Cites] Nature. 2009 Sep 17;461(7262):E4; discussion E5 [19759568.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74 [19805141.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3793-802 [19724059.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):181-9 [18176599.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] PLoS One. 2008;3(4):e1983 [18431473.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Annu Rev Immunol. 2000;18:423-49 [10837065.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Clin Lymphoma. 2000 Sep;1(2):110-6; discussion 117 [11707818.001]
  • [Cites] Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31 [11707860.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):113-5 [12086868.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):954-8 [12087404.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7042-9 [12460925.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):83-90 [12635171.001]
  • [Cites] Curr Opin Mol Ther. 2003 Feb;5(1):44-51 [12669470.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1860-4 [12702574.001]
  • [Cites] Nat Med. 2003 May;9(5):562-7 [12704383.001]
  • [Cites] Circ Res. 2003 Nov 28;93(11):1034-46 [14645134.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):331-3 [14667498.001]
  • [Cites] J Exp Med. 2004 Mar 15;199(6):775-84 [15007094.001]
  • [Cites] Cancer Treat Res. 2004;118:173-95 [15043193.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):215-6 [15254281.001]
  • [Cites] Cell. 2004 Jul 23;118(2):229-41 [15260992.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):641-8 [15286730.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] Science. 1998 Aug 21;281(5380):1191-3 [9712583.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • (PMID = 20023378.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA124515-04; United States / NCI NIH HHS / CA / R21 CA132026-03; United States / NIMHD NIH HHS / MD / L60 MD001952; United States / NCI NIH HHS / CA / CA124515-01A1; United States / NCRR NIH HHS / RR / P20 RR018787; United States / NCI NIH HHS / CA / R01CA124515; United States / NCRR NIH HHS / RR / P20RR018787; United States / NCI NIH HHS / CA / R21 CA132026-01A1; United States / NCI NIH HHS / CA / R21 CA132026; United States / NCI NIH HHS / CA / CA124515-02; United States / NCI NIH HHS / CA / R01 CA124515-01A1; United States / NCI NIH HHS / CA / R01 CA124515-02; United States / NCI NIH HHS / CA / R21CA132026; United States / NCI NIH HHS / CA / R01 CA124515; United States / NCI NIH HHS / CA / R01 CA124515-05; United States / NCI NIH HHS / CA / R01 CA124515-03S1; United States / NCI NIH HHS / CA / CA132026-01A1; United States / NCI NIH HHS / CA / R01 CA124515-03; United States / NCI NIH HHS / CA / R01CA124515-S3; United States / NCI NIH HHS / CA / R21 CA132026-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 0 / Transforming Growth Factor beta; 130068-27-8 / Interleukin-10; EC 3.5.3.1 / Arginase
  • [Number-of-references] 82
  • [Other-IDs] NLM/ NIHMS277625; NLM/ PMC3056209
  •  go-up   go-down


89. Micha JP, Goldstein BH, Zusman D, Rettenmaier MA, Epstein HD, Brown JV 3rd: Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report. J Reprod Med; 2007 Oct;52(10):971-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report.
  • BACKGROUND: The treatment for ovarian cancer has continued to improve, resulting in disease recurrence associated with previously unusual locations.
  • However, there are still very few documented cases involving treatment for ovarian cancer metastatic to the pericardium.
  • CASE: A 46-year-old woman was diagnosed with and treated for primary ovarian cancer in 1999.
  • In 2003 she developed ovarian cancer metastatic to the breast and was treated with additional chemotherapy.
  • CONCLUSION: There are a limited number of reported cases involving malignant pericardial effusions originating in an ovarian primary.
  • [MeSH-major] Adenocarcinoma / secondary. Heart Neoplasms / secondary. Ovarian Neoplasms / pathology. Pericardial Effusion / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17977179.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


90. Levy AD, Arnáiz J, Shaw JC, Sobin LH: From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics; 2008 Mar-Apr;28(2):583-607; quiz 621-2
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary malignant mesothelioma, multicystic mesothelioma, primary peritoneal serous carcinoma, leiomyomatosis peritonealis disseminata, and desmoplastic small round cell tumor are the most prominent of these rare lesions.
  • Primary peritoneal serous carcinoma occurs almost exclusively in women.
  • It is histologically identical to ovarian serous carcinoma and may be indistinguishable from metastatic ovarian carcinoma at imaging studies.
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Contrast Media. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Fibrosis / diagnosis. Fibrosis / pathology. Humans. Leiomyomatosis / diagnosis. Leiomyomatosis / pathology. Mesothelioma / diagnosis. Mesothelioma / pathology. Peritoneum / anatomy & histology. Peritoneum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349460.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 55
  •  go-up   go-down


91. Cowden Dahl KD, Zeineldin R, Hudson LG: PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res; 2007 May;5(5):413-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.
  • Elevated expression of the epidermal growth factor (EGF) receptor (EGFR) is detected in human ovarian tumors and is associated with decreased recurrence-free and overall survival.
  • PEA3, an ETS family transcription factor, is elevated in advanced and metastatic ovarian cancer and regulates MMPs in various cell types, therefore, we investigated whether PEA3 is required for the EGFR-dependent induction of MMP mRNA.
  • MMP-9 and MMP-14 mRNA levels were selectively increased in response to EGFR activity in ovarian tumor cells.
  • Furthermore, PEA3 overexpression was sufficient to induce MMP-9 and MMP-14 mRNA, tumor cell migration, and invasion, suggesting that PEA3 is an important contributor to the metastatic phenotype.
  • These results suggest that PEA3 is regulated by EGFR and that the elevated PEA3 expression detected in human ovarian cancer may divert cells to a more invasive phenotype by regulating MMP-9 and MMP-14.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1493-500 [11717538.001]
  • [Cites] J Rheumatol. 2001 Jul;28(7):1631-9 [11469472.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1375-84 [11562388.001]
  • [Cites] Int J Gynecol Pathol. 1992 Oct;11(4):266-72 [1399232.001]
  • [Cites] Eur J Cancer. 1993;29A(14):1951-7 [8280488.001]
  • [Cites] Br J Cancer. 1996 Feb;73(3):301-6 [8562334.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10672-80 [8631874.001]
  • [Cites] Cancer Lett. 1996 Sep 10;106(2):185-91 [8844971.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):60-8 [8986534.001]
  • [Cites] Genomics. 1997 Mar 1;40(2):222-33 [9119388.001]
  • [Cites] Oncogene. 1997 Aug 18;15(8):937-52 [9285689.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):155-65 [9490275.001]
  • [Cites] Mol Carcinog. 1998 Mar;21(3):194-204 [9537651.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):331-7 [9766568.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):221-8 [9888461.001]
  • [Cites] J Biol Chem. 1999 Feb 12;274(7):4347-53 [9933637.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5588-96 [10026175.001]
  • [Cites] Oncogene. 1999 Mar 4;18(9):1771-6 [10208438.001]
  • [Cites] Prostate. 1999 Aug 1;40(3):159-66 [10398277.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):715-20 [15756447.001]
  • [Cites] Reproduction. 2005 May;129(5):651-7 [15855628.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9280-6 [16230389.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):79-87 [16546322.001]
  • [Cites] Mol Carcinog. 2006 Nov;45(11):851-60 [16788982.001]
  • [Cites] J Cell Sci. 2002 Feb 15;115(Pt 4):839-48 [11865039.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45 [11988310.001]
  • [Cites] Methods. 2002 Jan;26(1):27-36 [12054902.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1412-9 [12684413.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):469-76 [12851697.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13 [14967450.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20794-806 [14990565.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1565-72 [15138601.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):418-24 [15238978.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):188-99 [15279711.001]
  • [Cites] Clin Exp Metastasis. 2004;21(3):191-9 [15387369.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1583-92 [1923525.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):529-35 [1548517.001]
  • [Cites] Int J Cancer. 1992 Sep 9;52(2):218-24 [1325950.001]
  • [Cites] Mol Pharmacol. 2000 Jul;58(1):145-51 [10860936.001]
  • [Cites] Clin Exp Metastasis. 1999;17(10):799-808 [11089877.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1370-83 [11158322.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1855-61 [11280738.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):551-7 [11297247.001]
  • (PMID = 17475671.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA119729-01; United States / NCI NIH HHS / CA / P20 CA888070; United States / NCI NIH HHS / CA / F32 CA119729; United States / NCI NIH HHS / CA / F32 CA119729-02; United States / NIEHS NIH HHS / ES / P30 ES012072; United States / NCI NIH HHS / CA / 1F32CA119729-01; United States / NCI NIH HHS / CA / R01 CA090492; United States / NCI NIH HHS / CA / CA119729-02; United States / NIEHS NIH HHS / ES / P30 ES-012072; United States / NCI NIH HHS / CA / CA119729-01; United States / NCI NIH HHS / CA / R01 CA90429
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transcription Factors; 0 / transcription factor PEA3; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS452280; NLM/ PMC3621069
  •  go-up   go-down


92. Zhao JZ, Wang G, Zhang RP, Liang H: [Clinicopathological features and prognosis of 68 patients with metastatic ovarian tumors from the gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Feb;13(2):129-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological features and prognosis of 68 patients with metastatic ovarian tumors from the gastric cancer].
  • OBJECTIVE: To investigate the clinicopathological features and prognosis of metastatic ovarian tumors from gastric cancer.
  • METHODS: Clinical data of 68 patients with metastatic ovarian carcinoma were reviewed retrospectively.
  • The majority of these patients was in the premenopausal state (67.6%) and had bilateral ovarian involvement (64.7%).
  • Pathological type was signet-ring cell carcinoma in 52.9% of the cases.
  • Univariable analysis revealed that resection of gastric cancer, lymphatic metastasis, pathologic type of metastatic ovarian tumor, extent of metastatic lesion, cytoreductive surgery and chemotherapy for metastatic ovarian carcinoma were associated with the prognosis.
  • Multivariable analysis revealed that cytoreductive surgery and extent of metastatic lesion were independent factors.
  • Patients with metastatic lesion confined to the ovaries had a median overall survival of 16.0 months as compared to 8.6 months for those with more extensive metastases (P<0.01), and had a median progression-free survival of 8.2 months as compared to 4.1 months for those with more extensive metastases (P<0.05).
  • CONCLUSIONS: Prognosis of patients with metastatic ovarian carcinoma from gastric cancer is quite poor.
  • Extent of metastatic lesion is an independent factor.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186624.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


93. Le T, Faught W, Hopkins L, Fung-Kee-Fung M: Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer? J Obstet Gynaecol Can; 2009 Jan;31(1):42-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?
  • OBJECTIVES: To examine the impact of delayed primary interval surgical debulking in women with ovarian cancer who show resistance to neoadjuvant platinum-based chemotherapy.
  • METHODS: We carried out retrospective chart reviews to identify women treated for ovarian cancer between 1997 and 2005 who were resistant to neoadjuvant platinum-based chemotherapy based on CA-125 criteria.
  • CONCLUSION: In women with ovarian cancer who have demonstrated platinum resistance after primary neoadjuvant chemotherapy, optimal tumour debulking can further improve response to subsequent platinum-based chemotherapy and prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Organoplatinum Compounds / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery


94. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK: Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer; 2006 Sep 15;107(6):1407-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
  • BACKGROUND: Epithelial ovarian cancer demonstrates high mortality due to diagnosis at an advanced stage.
  • In the search for a biomarker for early diagnosis and a target for therapy, the issue of whether interleukin-13 receptor (IL-13R), shown to be expressed on a variety of human cancers, is expressed in ovarian tumor samples was explored.
  • METHODS: IL-13R expression in 15 normal and 68 ovarian tumor tissue samples was determined by immunohistochemistry.
  • The efficacy of IL-13R-directed cytotoxin was determined in mice with subcutaneous, orthotopic, and peritoneal metastatic ovarian cancer.
  • RESULTS: Immunohistochemical analyses revealed that 83% of ovarian cancer specimens express IL-13Ralpha2, a high-affinity IL-13R subunit chain, whereas normal ovary samples expressed none or very low levels.
  • The majority of clear cell ovarian carcinomas with the worst prognosis showed strong staining for IL-13Ralpha2.
  • IL-13 cytotoxin was highly cytotoxic to the IGROV-1 ovarian cancer cell line in vitro, and it mediated significant antitumor activity against a xenografted tumor model.
  • The antitumor effects were confirmed by treating orthotopically implanted or peritoneal metastatic ovarian tumors, which showed significant extension of survival in immunodeficient mice.
  • CONCLUSIONS: IL-13Ralpha2 is a promising target for ovarian cancer therapy, and the soluble form of IL-13R may be a possible surrogate marker for disease monitoring.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cytotoxins / pharmacology. Interleukin-13 / pharmacology. Ovarian Neoplasms / drug therapy. Receptors, Interleukin / analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2006 by the American Cancer Society.
  • (PMID = 16902988.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytotoxins; 0 / IL13RA1 protein, human; 0 / Il13ra1 protein, mouse; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha1 Subunit; 0 / RNA, Messenger; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-13
  •  go-up   go-down


95. Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, Douchi T: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res; 2006 Jun;32(3):309-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
  • AIM: New biomarkers other than carbohydrate antigen (CA) 125 are needed for the detection of ovarian cancer.
  • We evaluated the preoperative plasma OPN level as a diagnostic biomarker for ovarian cancer in comparison with CA125.
  • METHODS: Preoperative plasma OPN and CA125 levels were measured and compared in 32 patients with ovarian cancer, 34 patients with benign ovarian tumor, 30 patients with other gynecologic cancers and 31 healthy women.
  • Preoperative plasma OPN levels were also assessed according to tumor stage, the volume of ascites and histological types.
  • The sensitivity and specificity for predicting ovarian cancer was compared between OPN and CA125.
  • RESULTS: Preoperative plasma OPN levels were significantly higher in patients with ovarian cancer than in those with benign ovarian tumor, in other gynecologic patients or in healthy women.
  • Stage IV ovarian cancer patients and ovarian cancer patients with ascites had higher plasma OPN levels than those without ascites and in a lower stage.
  • The sensitivity of preoperative plasma OPN in detecting ovarian cancer was 81.3% and almost reached that of CA125.
  • CONCLUSION: Preoperative OPN is a useful biomarker for predicting ovarian cancer.
  • Larger studies of patients with ovarian cancer showing a low CA125 level or in early stages of ovarian cancer are needed.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / blood. Sialoglycoproteins / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764622.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


96. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA: MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol; 2006 Mar;43(8):1129-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MT110 induced a costimulation independent polyclonal activation of CD4- and CD8-positive T cells as seen by de novo expression of CD69 and CD25, and secretion of interferon gamma, tumor necrosis factor alpha, and interleukins 2, 4 and 10.
  • MT110 was highly efficacious in a NOD/SCID mouse model with subcutaneously growing SW480 human colon cancer cells.
  • Finally, MT110 could eradicate patient-derived metastatic ovarian cancer tissue growing under the skin of NOD/SCID mice.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139892.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Antigens, CD3; 0 / MT110 monoclonal antibody; 0 / Recombinant Proteins; 0 / Single-Chain Antibodies
  •  go-up   go-down


97. Khan SM, Funk HM, Thiolloy S, Lotan TL, Hickson J, Prins GS, Drew AF, Rinker-Schaeffer CW: In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin Exp Metastasis; 2010 Mar;27(3):185-96
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro metastatic colonization of human ovarian cancer cells to the omentum.
  • Despite the potentially crucial contributions of the omentum in the regulation of ovarian cancer metastatic growth, it remains a poorly understood organ.
  • Further experiments demonstrate that the ex vivo culture conditions allow for the proliferation of ovarian cancer cells in vitro and support a similar pattern of microscopic lesions after either intraperitoneal injection of ovarian cancer cells or co-culture of ovarian cancer cells with the omentum.
  • In agreement with previous studies from our laboratory, histologic evaluation of these specimens found that ovarian cancer cells, as well as other peritoneal cancer cells, preferentially accumulate in, and colonize, omental areas rich in immune cells.
  • [MeSH-major] Omentum / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Tissue Res. 1979 Sep 3;201(2):327-30 [315819.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1228-32 [9102203.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):253-64 [19242414.001]
  • [Cites] Differentiation. 2007 Jan;75(1):1-11 [17244017.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2264-70 [16489030.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):303-7 [9935214.001]
  • [Cites] Kidney Int. 1990 Jun;37(6):1563-70 [2362409.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1739-52 [17071597.001]
  • [Cites] Cancer Microenviron. 2008 Dec;1(1):1-11 [19308680.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):17-30 [15946832.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):269-74 [10985879.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):374-84 [12865932.001]
  • [Cites] Exp Cell Res. 1971 Dec;69(2):313-23 [5163630.001]
  • [Cites] Perit Dial Int. 1989;9(4):341-7 [2488391.001]
  • [Cites] Radiology. 1988 Dec;169(3):691-4 [3186993.001]
  • [Cites] Surg Clin North Am. 2000 Feb;80(1):275-93, xii [10685153.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1994 Mar;30A(3):145-7 [25939161.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2166-75 [18381422.001]
  • [Cites] Immunol Res. 2009 Dec;45(2-3):185-94 [19253004.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1463-72 [17546601.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):265-74 [18937969.001]
  • [Cites] Arch Surg. 1981 Jan;116(1):99-106 [6258537.001]
  • [Cites] Anat Rec. 1948 Jul;101(3):333-51 [18873152.001]
  • [Cites] Anat Embryol (Berl). 2005 Feb;209(3):251-61 [15662530.001]
  • [Cites] Cell Biol Int. 2001;25(5):445-50 [11401332.001]
  • [Cites] Virchows Arch. 1994;424(1):59-67 [7981905.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1070-6 [16875720.001]
  • [Cites] Pathol Res Pract. 2003;199(5):341-4 [12908525.001]
  • [Cites] J Soc Gynecol Investig. 1999 Nov-Dec;6(6):333-40 [10643588.001]
  • (PMID = 20229256.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES015584; United States / NCI NIH HHS / CA / 2R01CA089569-06A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


98. Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M, Malvasi A: An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics; 2009 Jun;10(4):240-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings.
  • Among the gynaecological malignancies, ovarian cancer is one of the neoplastic forms with the poorest prognosis and with the bad overall and disease-free survival rates than other gynaecological cancers.
  • Ovarian tumors can be classified on the basis of the cells of origin in epithelial, stromal and germ cell tumors.
  • Epithelial ovarian tumors display great histological heterogeneity and can be further subdivided into benign, intermediate or borderline, and invasive tumors.
  • Several studies on ovarian tumors, have focused on the identification of both diagnostic and prognostic markers for applications in clinical practice.
  • High-throughput technologies have accelerated the process of biomolecular study and genomic discovery; unfortunately, validity of these should be still demonstrated by extensive researches on sensibility and sensitivity of ovarian cancer novel biomarkers, determining whether gene profiling and proteomics could help differentiate between patients with metastatic ovarian cancer and primary ovarian carcinomas, and their potential impact on management.
  • In this review, the current state of knowledge about the genoproteomic and potential clinical value of gene expression profiling in ovarian cancer and ovarian borderline tumors is discussed, focusing on three main areas: distinguishing normal ovarian tissue from ovarian cancers and borderline tumors, identifying different genotypes of ovarian tissue and identifying proteins linked to cancer or tumor development.
  • By these targets, authors focus on the use of novel molecules, developed on the proteomics and genomics researches, as potential protein biomarkers in the management of ovarian cancer or borderline tumor, overlooking on current state of the art and on future perspectives of researches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):568-74 [11709277.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):282-5 [11553857.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8018-23 [11416160.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):4965-8 [11326648.001]
  • [Cites] Oncogene. 2009 Mar 5;28(9):1206-17 [19151754.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):475-80 [19150122.001]
  • [Cites] Int J Biochem Cell Biol. 2009 May;41(5):1034-45 [18930836.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):134-44 [19088723.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1353-60 [18951210.001]
  • [Cites] Biochem Pharmacol. 2008 Sep 15;76(6):707-16 [18644348.001]
  • [Cites] Endocrinology. 2008 Aug;149(8):3809-16 [18450971.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):2102-11 [18396168.001]
  • [Cites] Histol Histopathol. 2008 Aug;23(8):935-44 [18498068.001]
  • [Cites] Mol Cancer Res. 2008 May;6(5):695-705 [18505915.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4127-34 [17939699.001]
  • [Cites] Micron. 2007;38(8):824-33 [17709250.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):725-31 [17610223.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2509-17 [17547437.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1993-2002 [17620429.001]
  • [Cites] Cancer. 2007 May 1;109(9):1887-96 [17373668.001]
  • [Cites] Ann Oncol. 2007 May;18(5):881-5 [17301071.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):10-5 [17197890.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):924-31 [16842844.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2730-40 [17063503.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 [17077358.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1511-9 [16944535.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9017-25 [16982743.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1407-18 [16902988.001]
  • [Cites] Clin Obstet Gynecol. 2006 Sep;49(3):433-47 [16885651.001]
  • [Cites] EMBO Rep. 2006 Jun;7(6):599-604 [16741504.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(2):171-6 [16620064.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):397-406 [16549852.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):62-70 [16445817.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9338-43 [16361633.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Am J Obstet Gynecol. 2005 Nov;193(5):1630-9 [16260202.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9415-25 [16230405.001]
  • [Cites] Mol Endocrinol. 2005 Oct;19(10):2564-78 [15928314.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5764-74 [16123809.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):618-23 [16014115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1729-36 [15841084.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):461-9 [15691647.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Nat Med. 1999 Aug;5(8):938-42 [10426319.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):849-51 [10216504.001]
  • [Cites] Clin Chem. 1999 May;45(5):651-8 [10222351.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):922-8 [9269828.001]
  • [Cites] Genomics. 1997 Mar 1;40(2):371-4 [9119409.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Sep;84(18):6379-83 [2819873.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):35-49 [15027884.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):761-8 [14984938.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10):1067-78 [14578472.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):764-8 [14514780.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):382-9 [12915129.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):433-73 [12663865.001]
  • [Cites] Nature. 2002 Nov 7;420(6911):19 [12422186.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):41-7 [11163149.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] Adv Cancer Res. 2000;77:81-137 [10549356.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):103-8 [17479670.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):83-8 [17479666.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1440-50 [17315909.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1295-305 [17291023.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):348.e1-5 [17403417.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1670-9 [17308108.001]
  • [Cites] Trends Biotechnol. 2007 Mar;25(3):111-8 [17257698.001]
  • [Cites] J Proteome Res. 2007 Feb;6(2):772-80 [17269733.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4943-8 [17214367.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):332-40 [17154180.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):47-59 [11960694.001]
  • [Cites] Br J Nutr. 2002 Jan;87 Suppl 1:S23-9 [11895152.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • (PMID = 19949545.001).
  • [ISSN] 1875-5488
  • [Journal-full-title] Current genomics
  • [ISO-abbreviation] Curr. Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2709935
  • [Keywords] NOTNLM ; Ovarian cancer / borderline ovarian tumors / genomics / markers / oncogenes. / proteomics
  •  go-up   go-down


99. Hurtado A, Tseng JC, Meruelo D: Gene therapy that safely targets and kills tumor cells throughout the body. Rejuvenation Res; 2006;9(1):36-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors studied the therapeutic value of Sindbis vectors for advanced metastatic cancer by using a variety of clinically accurate mouse models and demonstrated through imaging, histological, and molecular data that Sindbis vectors systemically and specifically infect/detect and kill metastasized tumors in vivo, leading to significant suppression of tumor growth and enhanced survival.
  • Use of two different bioluminescent genetic markers for the IVIS Imaging System (Xenogen Corp., Alameda, CA) permitted demonstration of an excellent correlation between vector delivery and metastatic locations in vivo.
  • These results suggest that Sindbis viral vectors may be promising agents for both specific detection and growth suppression of metastatic ovarian cancer.
  • [MeSH-major] Genetic Therapy. Genetic Vectors. Ovarian Neoplasms / therapy. Sindbis Virus

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608394.001).
  • [ISSN] 1549-1684
  • [Journal-full-title] Rejuvenation research
  • [ISO-abbreviation] Rejuvenation Res
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100687; United States / NCI NIH HHS / CA / CA22247; United States / NCI NIH HHS / CA / CA68498
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


100. Gao R, Shen Y, Cai J, Lei M, Wang Z: Expression of voltage-gated sodium channel alpha subunit in human ovarian cancer. Oncol Rep; 2010 May;23(5):1293-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of voltage-gated sodium channel alpha subunit in human ovarian cancer.
  • We report the possible roles of VGSC in human ovarian cancer.
  • Relative mRNA expression levels of Nav1.1, Nav1.3, Nav1.4 and Nav1.5, analyzed by RT-PCR, were significantly higher in ovarian cancers cells compared with normal ovarian tissues; relative mRNA expression levels of Nav1.2, Nav1.4, Nav1.5 and Nav1.7 were significantly increased in highly metastatic ovarian cancer cells (Caov-3 and SKOV-3) compared with low-metastatic ovarian cancer cells (Anglne).
  • Real-time PCR, Western blot analysis and immunohistochemistry assays revealed that functional expression levels of Nav1.5 might be correlated with the grade and metastasis of ovarian cancer.
  • Our findings suggested that abnormal expression of Nav1.5 could be an integral component of the metastatic process in human ovarian cancer and might serve as a therapeutic target in ovarian cancer treatment.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Muscle Proteins / metabolism. Ovarian Neoplasms / metabolism. Sodium Channels / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TETRODOTOXIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20372843.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / NAV1.1 Voltage-Gated Sodium Channel; 0 / NAV1.3 Voltage-Gated Sodium Channel; 0 / NAV1.4 Voltage-Gated Sodium Channel; 0 / NAV1.5 Voltage-Gated Sodium Channel; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / SCN1A protein, human; 0 / SCN3A protein, human; 0 / SCN4A protein, human; 0 / SCN5A protein, human; 0 / Sodium Channel Blockers; 0 / Sodium Channels; 4368-28-9 / Tetrodotoxin
  •  go-up   go-down






Advertisement